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Abstract
Problem: Adolescents and young adults (AYA) ages 13 to 24 comprise a quarter of the new
HIV diagnoses in the United States. Lack of access to HIV-preventive therapies such as preexposure prophylaxis (PrEP) reduces opportunities to prevent HIV infection in this population.
Initiating PrEP in AYA significantly reduces the negative health outcomes of HIV, but it is
evident that many clinicians are still reluctant to initiate PrEP in AYA patients based on
perceived threats and barriers.
Context: Primary care clinics, including school-based clinics, have an opportunity to offer HIV
prevention services including PrEP. This project, the Adolescent and Young Adult
Comprehensive PrEP Education Project (AYA ComPrEP) is an HIV-prevention quality
improvement project that is directed towards providing AYA high-risk populations with
access to PrEP in the primary care setting. The project was supposed to be completed at
the Balboa Teen Clinic of Balboa High School, a clinic serviced by the Community
Health Programs for Youth (CHPY) of the San Francisco Department of Public Health
(SFDPH). Due to the COVID-19 pandemic shelter-in-place policy, the training for clinicians
and staff, and roll out of PrEP service for adolescent clients of Balboa Teen Clinic was deferred
to an unknown date. An online training and simulation for the University of San Francisco
clinicians (nurse practitioner students) was conducted instead.
Interventions: A site feasibility analysis was conducted, which include consultations with
CHPY leadership and management, site assessment, conduct of face-to-face in-depth interviews
among staff of Balboa Teen Clinic, and review of literature and best practices to develop
recommendations for a pilot PrEP program for AYA. Some interventions were modified to
focus on increasing the confidence of providers, nurse practitioners students of the
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University of San Francisco (USF) to prescribe PrEP to AYA. The focus of this DNP
project was shifted to designing modules, conducting and evaluating of an online simulation, a
PrEP training workshop for providers. The simulation include didactic, role play, case studies
covering information, best practice recommendations on HIV and AIDS, HIV counseling,
reproductive health, sexual orientation and gender identity initiative, and PrEP for AYA.
Measures: A pre-assessment and post-simulation evaluation was utilized to determine the
change in providers’ knowledge, enabling attitudes, confidence, and readiness to offer HIV
prevention services, and prescribe PrEP in preparation for their integration in clinics that they
will be working. Case studies in the form of simulated patients to measure how they would apply
the knowledge and confidence gained towards real life practice scenarios.
Results: Nineteen clinicians attended the online PrEP simulation training-workshop. The data
analysis revealed a 17.11% increase in HIV/AIDS & PrEP knowledge mean score (average
scores: 76% for pre-simulation versus 89% for post-simulation) among participants. Likewise,
HIV and PrEP enabling or non-stigmatizing attitude scores has increased by 18.3% (average
scores: 71% for pre-simulation versus 84% for post-simulation). All the 19 clinicians revealed
that their knowledge and confidence to prescribe PrEP to adolescents and young adults in their
practice has increased as a result of attending the simulation (13 strongly agreed; 6 agreed) as
compared to 2 clinicians prior to the simulation.
Conclusions: PrEP targeted for at-risk AYA is necessary to reduce HIV rates. This is possible
by breaking barriers to PrEP prescription through education and training of clinicians. PrEP
should be included in the training and preparation of clinicians to address the adolescent and
young adult populations. Online simulation training workshop for PrEP is an effective alternative
means if face-to-face training is not possible.
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Section II—Introduction
Background and Problem Description
Human immunodeficiency virus (HIV) infection has claimed millions of lives across the
world (UNAIDS, 2019). The Joint United Nations Program on HIV & AIDS (UNAIDS) and the
World Health Organization (WHO) estimates that 36.9 million people worldwide were living
with HIV in 2017 (UNAIDS, 2019). In the United States in 2017, the Centers for Disease
Control and Prevention (CDC) reported 38,739 new HIV diagnoses, with an estimate of
1,100,000 people of all ages currently living with HIV in the U.S. (CDC, 2018). Around 15%
(one out of seven) people living with HIV in the country are not aware that they are infected
(CDC, 2018). More than half of the new HIV infections were from the southern part of the
country. The annual rate of new HIV diagnoses in the U.S. has decreased compared to a decade
ago, but for the last several years (2012-2016) has remained stable rather than decreasing. The
CDC has indicated that this is due to inadequate outreach to those who could most benefit,
primarily disproportionately affected populations in the south such as African Americans and
Latinos/Hispanics (CDC, 2018).
Adolescents and young adults aged 13 to 24 represent approximately 15% of the U.S.
population according to U.S. Census Bureau (2017). In 2015, at least 22% of new HIV diagnoses
in the U.S. were among adolescents and young adults (AYA) between the ages of 13 and
24 (CDC, 2018). Men having sex with men (MSM) constituted the gender group with the most
substantial number of new HIV infections (81%) among young people. Lack of access to PrEP
prophylaxis reduces the opportunity to prevent HIV infection in this population (Hosek et al.,
2016). Approximately half of AYA, particularly adolescents and young men having sex with
men (AYMSM), have poor health outcomes with low retention in care, and low viral-load
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suppression (CDC, 2018). Acquiring HIV at a young age means lifelong management of chronic
HIV infection. This has economic and psychosocial implications for every individual infected by
HIV, for society, and for public health practice worldwide. The lifetime cost per patient for HIV
care in 2018 in the U.S. was $485,000 (CDC, 2020).
HIV is a virus that weakens the immune system by destroying certain types of white
blood cells called CD4-T cells (also known as CD4 cells). These lymphocytes help to coordinate
an immune response by invoking B cells (which produce antibodies), as well as macrophages,
and other types of T cells that also fight infection (U.S. HHS, 2019). The virus is spread through
certain body fluids including semen, vaginal fluids, blood, and breast milk. When HIV enters the
body, it takes three weeks to three months for the body to develop HIV antibodies that can be
detected through an HIV antibody test (HAT). It takes around 3-4 weeks for a newly infected
person to seroconvert from HIV negative to HIV positive, a condition which the person may or
may not experience an acute viral illness. When a person is infected with HIV, the virus destroys
CD4 cells, reducing them to low levels, inhibiting immune protection, and increasing viral load
levels. As a result, the infected person is more susceptible to opportunistic infections such as
tuberculosis, toxoplasmosis, pneumonia and certain types of cancers such as Kaposi’s sarcoma
(CDC, 2018). HIV infection is primarily spread through anal and vaginal sex, as well as shared
needles or syringes, a common practice among people who inject drugs (CDC, 2018). Other
modes of transmission such as mother-to-child and needle stick injury are less common in the
U.S., and while there is a risk, it is extremely rare cases to contract HIV through oral sex or
blood transfusion (CDC, 2018). Improved health care, including access to HIV services, harm
reduction programs such as needle exchange services, and PrEP play a role in the reduction of
HIV transmission in western countries including the U.S. (CDC, 2018).
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In the three decades since the first wave of the epidemic, various interventions have
emerged to improve strategies for preventing HIV, including the use of pharmaceuticals for preexposure prophylaxis (PrEP). Among adolescents, HIV infections still continue at a high rate
(CDC, 2018) despite increased programs targeting key populations through HIV education and
the availability of preventive medications (PrEP), as well as post-exposure prophylaxis (PEP)
and other effective antiviral treatment for people living with HIV.
What is PrEP?
Pre-exposure prophylaxis (PrEP) for HIV includes medications and other delivery
devices that prevent HIV transmission. Currently, Truvada™ and Descovy™ are the only two
pharmaceutical interventions in oral form that shown in clinical trials to prevent HIV
transmission that has approval by the FDA (CDC, 2019). Other methods of PrEP include other
delivery devices such as injections, implants, and vaginal rings. They are still under clinical
trials. This medication, Truvada™, is a combination tenofovir disoproxil fumarate (TDF) and
emtricitabine (FTC). These drugs have been used effectively to manage HIV infection since
1996 and are known for their safety profile together and in combination with other forms of antiretroviral drugs (e.g. efavirenz) as treatment for HIV infection. In 2012, Truvada™ was found
through clinical trials to be more than 90% effective in preventing sexual transmission of HIV
among high-risk HIV-negative populations such as men who have sex with men, and 70%
effective for those who inject drugs. PrEP is relatively safe and the CDC (2019) reports that no
significant side effects have been seen in HIV-negative persons who have been taking PrEP for
up to 5 years. However, potentially serious side effects of Truvada that warrant monitoring
include kidney problems, lactic acidosis, severe liver problems, and bone loss (Gilead Sciences,
2019). It is recommended that HIV-negative persons be tested for kidney and liver function and
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that healthcare providers rule out hepatitis infection and bone problems before prescribing
continuous Truvada.
PrEP as a pharmacologic intervention, became available for adult men who have sex with
men (MSM) was initiated in July 2012 when the U.S. Federal Drug Administration (FDA)
approved Truvada® taken once daily to prevent the sexual transmission of HIV. Though the U.S.
is the first country to implement PrEP, data reveals that from 2012 to 2015, a meager percentage
of PrEP prescriptions (7.6%) were provided for youth under the age of 25 (Bush et al., 2016).
Limited clinician knowledge and comfort in the use of PrEP, along with the absence of FDA
indications for PrEP use in this population prior to 2018 have contributed to the low rate of new
PrEP prescriptions in young people (Hosek et al., 2016). Likewise, some providers lack
awareness of statutes allowing treatment of adolescents for sexually transmitted infections (STI)
prevention without parental notifications, and limited adolescence-focused healthcare services
reduce the use of PrEP among this group.
The patent for Truvada expired in December 2017 and other countries have ruled against
the extension of patency rights of Truvada, making it available for overseas pharmaceutical
companies to create generic versions of Truvada (TDF/FTC) to be used as pre-exposure
prophylaxis. This reduces the cost of Truvada to approximately $10 per bottle in countries such
as Australia, significantly lower than the cost in the U.S., where the medication has been priced
at $2,000 per bottle. Currently, the original manufacturer, Gilead has a program to waive co-pays
to those who are taking anti-retroviral medications both for non-positive patients (PrEP) and
those living with HIV (in treatment).
New PrEP Formulation. In October 2019, the FDA approved a safer version of
tenofovir, the tenofovir alafenamide or TAF in combination with emtricitabine or FTC known as
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Descovy™ for cisgender males (men who have sex with men and transgender women). It is
found to be equally effective to Truvada but less toxic and has fewer side effects, particularly in
kidney functions and bone demineralization (Krakower, Daskalakis, Feinberg, Marcus, 2020).
The result from the study of 5,300 cisgender men who have sex with men and transgender
women in North America and Europe revealed that HIV pre-exposure prophylaxis regimen
utilizing Descovy™ was found to be superior to the traditional regimen with Truvada™ with
more than 90% effectiveness (Schoen, J., 2019).
Alternative PrEP Dosing. Daily adherence to PrEP remains a challenge to some patients
and consequently to providers. PrEP providers face issues prescribing PrEP and at the same time
ensuring adherence and avoiding viral resistance to Truvada. In other parts of the world such as
France, the UK, Canada, and Australia, alternative dosing to daily PrEP is available. Some of the
alternative PrEP dosing evaluated in various studies (Appendix A) across the world includes ondemand PrEP, event-driven PrEP, time-driven PrEP, and intermittent PrEP. While this may not
yet be widely practiced in the United States and is limited to studies, alternative PrEP dosing
may become more available in later years. In a Kenyan study, Mutua et al (2012) suggested that
adherence to intermittent dosing may be more difficult than adherence to daily dosing, but still
may be effective in preventing HIV infection if minimum effective concentrations of the drug are
attained. In the latest Paris study of Molina et al (2018), intermittent dosing has shown similar,
successful profiles in comparison with daily dosing. The Prevenir ANRS study in Paris has high
retention rates with good safety profiles for both intermittent and daily PrEP groups (Molina et
al., 2018). Alternative dosing of PrEP has the potential to minimize costs, decrease toxicity or
adverse events, improve adherence, and increase HIV prevention in populations with alternative
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lifestyles such as those working in the sex trade, recreational drug users, and the homeless (Volk
et al., 2012).
It is important that clinicians are up to date with new information, research, and practices
provided by the guidelines. Insight into maintaining effectiveness of HIV prevention using a
daily dosing regimen of PrEP or alternative dosing will facilitate understanding of what
constitutes a safe and acceptable PrEP intake. This could lead to change and stronger policies
and protocols that support alternative dosing of Truvada, particularly in settings with limited
resources and in populations for whom daily PrEP pill intake remains an issue.
Clinical Practice Guidelines on PrEP
The CDC released the first interim guidance for the use of preventive medication (PrEP),
in 2012, in sexually active adult MSM who are at substantial risk of acquiring HIV infection
(CDC, 2014). The risk for HIV is based on patterns of anal sex, use of condoms, multiple
partners, monogamous relationships, HIV status of a partner, and positive diagnosis of sexually
transmitted infection (CDC). In May 2014, the United States Public Health Service released the
first clinical practice guidelines for daily oral pre-exposure prophylaxis (PrEP) (CDC). This was
updated in 2016 and 2017, which included revisions to several sections of the guidelines. The
latest 2017 updates did not change the recommendation for the use of PrEP in the U.S; rather it
included a call for the development of evidence-based studies and clarification on specific points
in clinical care (CDC, 2018). For example, a preference for antigen/antibody testing whenever
available, rather than antibody-only tests, is now recommended. Also, the use of a 3, 000
copies/mL cut-off for suspected false-positive viral load tests was set (CDC, 2018). The CDC
(2018) added information on hepatitis C screening in relation to PrEP to be consistent with the
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guidance of the 2017 American Association for the Study of Liver Diseases (AASLD) and the
Infectious Disease Society of America (IDSA).
The current CDC guidelines for men who have sex with men (MSM) were found to
reduce the incidence and prevalence of HIV infection in the U.S. Projecting the data forward,
based on the study by Jennesse et al. (2016), a 40% coverage of PrEP for MSM in the U.S. could
potentially prevent 1,162 new infections per 100,000 persons (33% of infections). In the study of
Goodreau et al. (2017), initiating PrEP for adolescent sexual minority males six months after
their first anal sex at 40% coverage among this group is projected to prevent 27.8% of HIV
infections. Despite the effectiveness of PrEP in preventing the transmission of HIV, the U.S.
registers low utilization of Truvada (CDC, 2018). Local health departments and public health
clinics across the U.S. were the main source of prescriptions for Truvada, however, PrEP
implementation remains at very low rates (Weiss, Smith, Newman, Wiener, Kitlas, Hoover,
2018).
Low utilization or the lack of taking Truvada for those who are at risk is seen by those
who are significantly impacted by recent HIV infections, African Americans and Latinos, the
populations that account for the highest proportions of new HIV infections in the U.S (CDC,
2019). Despite accounting for 13% of the total population in the U.S., African Americans had a
43% (16,694) of the 38,739 new HIV diagnoses in 2017 (CDC). The majority (60%) of the new
infections among African Americans were gay and bisexual men, while a quarter (26%) were
among women. Yet of the 78,360 persons who filled prescriptions for Truvada™ in the U.S. in
2016, only 11.2% were African American while and only 13.1% were Hispanic, compared to
68.7% white. Although there was a 5% decrease in new HIV infections in African Americans
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from 2010 to 2016 among gay and bisexual men ages 13-24, there was an increase of 40% in
new HIV infections among African Americans ages 25-34 (CDC, 2019).
Problem Description
PrEP in San Francisco
The San Francisco Department of Public Health first implemented a PrEP program in
2012, when Truvada™ was approved as an HIV-prevention pill. Young people in San
Francisco have had access to PrEP since 2016, as an off-label medication through the clinics
of the Community Health Programs for Youth (CHPY). Cole Street Clinic and Larkin Street
Clinic, two CHPY facilities, have been providing PrEP as an off-label prescription to its mostat-risk AYA patients based on the judgment of the clinician and the circumstances of the
patients. Factors in prescribing PrEP typically include insurance coverage for Truvada and
ease of PrEP delivery, but not necessarily the emerging risks of the patient. As of 2018, in a
landmark achievement, the FDA increased access to PrEP for patients under age 18. This new
guideline aims to provide opportunities for clinicians to prescribe PrEP for at risk AYA (CDC
2014).
HIV Prevalence in San Francisco
In San Francisco, aggressive collective efforts are paying off with record-low number of
new HIV cases. The SFDPH is a major partaker in the ‘Getting to Zero’ initiative of the World
Health Organization and the United Nations and will benefit from this project. This ambitious
initiative aims to achieve zero new HIV infections, zero HIV deaths, and zero HIV-related
stigma by 2020. It is San Francisco’s vision to reduce HIV transmission and HIV-related deaths
by 90% in 2020 as part of this initiative. The City and County of San Francisco have been
performing well in recent years to meet the target, outpacing national efforts to reduce HIV
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infection with only about 221 reported cases in 2017, reported by SFDPH Population Health
Division (2018). This was achieved by providing access to HIV medications for people living
with HIV and PrEP for high-risk persons. The latest 2017 HIV data records the lowest number of
new HIV cases for San Francisco since the HIV epidemic in the 1980s (SFDPH Population
Health Division, 2018). The face of San Francisco’s HIV epidemic reflects more Caucasian
whites in higher numbers as compared to African Americans and Latinos, which is reflective of
the national epidemic.
Risk Among Youth and Young Adults. Since 2014, San Francisco public health
efforts have been directed toward reducing HIV transmission among young people who are
most at risk (SFDPH Population Health Division, 2018). In 2017, of the 221 new HIV
infections in San Francisco, more than 60% are younger than 40 years old (SFDPH Population
Health Division, 2018). Over 100 of the people living with HIV who reside in the city are ages
13-24 as of December 2017 (SFDPH Population Health Division, 2018).
HIV in the African American Community. Despite low numbers of new HIV
infections within San Francisco, the annual rate of new HIV shows an increase among African
Americans in 2017, with African American men reaching triple times higher rates of HIV than
of white men. Rates were also eight times higher for African American women than Caucasian
women (SFDPH Population Health Division, 2018). Public health efforts to engage African
American men in prevention programs hopes to curb these increases and bring rates to a lower
level in this group.
Needs within the Homeless Population. While PrEP and HIV treatment for people
living with HIV in San Francisco is available, there is the need for better services and outreach
programs for homeless people; many are adolescents and young adults. Currently, less than a
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third of homeless people living with HIV are virally suppressed (SFDPH Population Health
Division). Issues of safe storage of medications and mental health or substance abuse disorders
that affect treatment play a role in reaching the city goal for zero new HIV infection by 2020
(SFDPH Population Health Division). Our best opportunity at this time is to make PrEP
accessible to everyone, with emphasis on the needs of vulnerable populations, which include
young people, African Americans, Hispanic, and the homeless.
Adolescent and Young Adult Access to PrEP in San Francisco
The Community Health Programs for Youth (CHPY) is part of the San Francisco Health
Network (SFHN) in the San Francisco Department of Public Health (SFDPH). Comprised of
more than eight major and satellite specialty clinics across San Francisco, CHPY provides
comprehensive clinical services for adolescents and young adults (AYA) age 12-25, including
those who are transgender and homeless (SFHN, 2018).
An estimated 15,952 are people living with HIV in San Francisco with 221 new cases in
2017. Around 11% of new HIV infections in 2017 occurred in ages 13-24, with 18% in ages 2529 years old, and 33% in ages 30-39 years old (SFDPH Population Health Division, 2018).
CHPY provides medical services to young people living with HIV in the city, particularly the
homeless, through its Larkin Street Clinic and Cole Street Clinic. CHPY works in partnership
with the Larkin Youth Services to give medical care through its ACAC (Assisted Care-After
Care Program) HIV Specialty Clinic to young people living with HIV, housed in a residential
program facility on Hyde Street.
Currently, there is no standard assessment template in the electronic record that CHPY
clinicians can use to do risk assessment and identify PrEP candidates. Sexual history and other
risk behavior assessments are being performed inconsistently based on the observation of this
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author. Enrollment in PrEP is merely based on the clinician’s individual judgment or
preference or at the patient’s request (although we know from the literature that a significant
percentage of young people are unaware of the availability of PrEP). There is a significant
need to make PrEP available to more at-risk AYA patients of CHPY utilizing a standardized
approach. Assessment of the perceived roles of CHPY nurses in PrEP education for youth is
also needed to understand the challenges of PrEP delivery and to improve clinical and nursing
practices with regard to PrEP.
The adolescent group at CHPY is a diverse population. Some adolescents are men having
sex with men, others are sexually active transgender, or adolescents who engage in sex work
and/or drug use. The complexity of this age group for PrEP delivery is worth understanding.
Protocols should exist to inform primary care providers and to support these at-risk populations
in navigating the healthcare system to better address their HIV prevention needs. Adoption of the
CDC guidelines for AYA MSM (Goodreau et al., 2017) could reduce the high rate of HIV
infections in this age group. Based on the consultations and interviews, not all staff and primary
care team members at CHPY are aware of the updated CDC PrEP guidelines and protocol. The
current CDC guidelines could be adopted and modified to address the relevance of PrEP for atrisk adolescents, highlighting the role of clinicians and other members of the healthcare team,
including nurse practitioners and nurses.
Available Knowledge: Barriers to PrEP as a Preventive Service for AYA
Literature Search. A comprehensive literature search on barriers to PrEP utilization was
performed using CINAHL Complete, PubMed, Fusion, EBSCO, and Cochrane with the date
range January 1, 2012, to June 1, 2019. The author chose these dates because Truvada® and the
PrEP intervention protocol became available in 2012. The initial search using the terms
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“nursing” and “HIV prevention” yielded around 145 articles. Further inclusion criteria provided
access to studies in the biomedical sciences on preventing HIV. The author applied the following
search terms across all databases: PrEP, pre-exposure prophylaxis, barriers, adolescents, nursing,
and clinicians, which yielded approximately 65 published papers. Barriers were classified as
either prescriber-associated barriers, or AYA patient-associated barriers. Although only U.S.
studies were included in the review, studies from other countries and those involving different
age groups were used as a basis of reference to verify the findings of this evaluation.
Evaluation of the Evidence. Nine articles met the inclusion criteria and were selected
for final review. The evidence was rated using the John Hopkins Nursing Evidence-Based
Practice Appraisal Tool. The table in the Appendix B present the evidence assessed in this
review, categorized according to provider-associated and patient-associated barriers in AYA
PrEP use. All of the examined evidence provided explicit aims, findings on barriers to AYA
PrEP use, and recommendations for application in clinical practice and for future research. Due
to the limited number of studies available specifically on barriers to AYA PrEP use, the author
included articles with both high quality (Rating A) as well as those of with good quality (Rating
B). The appraisal rating of B was given to study results that do not appear to be generalizable,
due to the small sample size or other limitations (Refer to Appendix B).
The articles on PrEP services that were selected for review included four studies
emphasizing the attitudes of PrEP prescribers (i.e. physicians or nurse practitioners). Despite the
small sample size of the clinician studies, they provide an in-depth understanding of providers’
viewpoint, intentions, practices, and response to the CDC PrEP guidelines.
Clinician Barriers to PrEP as Preventive Service for AYA
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Drawing on research experience and data, recommendations for the modification of
existing PrEP guidelines can be developed to benefit adolescents and young adults at risk of HIV
infection. Tables in the Appendix A provide a synopsis on barriers to PrEP use in adolescents
and young adults, categorized according to 1) provider-associated barriers in AYA PrEP use and;
2) AYA patient-associated barriers. Studies involving clinicians included a total of 233 providers
who had experience with medications used for PrEP. Mullins et al looked at the attitudes of
clinicians toward the CDC PrEP guidelines (Mullins, Lally, Zimet, & Kahn, 2015), attitudes of
providers towards PrEP (Mullins, Zimet, Lally, & Kahn, 2016), the relationship between
intention to prescribe PrEP and actual prescription (Mullins, Zimet, Lally, Xu, Thornton et al,
2017), and youth access to PrEP in relation to providers willingness to prescribe PrEP to youth
(Hart-Cooper, Allen, Erwin, & Scott, 2018).
Clinicians’ attitudes toward AYA using PrEP. Study findings reveal that clinicians
reported greater intention to prescribe PrEP to adults as compared with adolescents (Mullins et
al, 2015). Providers faced challenges in prescribing PrEP to AYA, particularly those below 18
years of age, due to lack of clarity that PrEP falls under protected confidential care for
adolescents, which does not require parental consent (Mullins et al, 2016). Concern about
maintaining confidentiality and involvement of parents of AYA is common among providers.
The majority of clinicians are not concerned about the off-label use of PrEP for those below 18.
However, clinicians have differing views about adolescence patients’ ability to understand PrEP
benefits and risks and give true informed consent (Mullins et al). Issues on maintaining
confidentiality and parental involvement were common among providers. A significant number
of providers expressed a lack of clarity that PrEP falls under protected confidential care for
adolescents, which does not require parental consent (Mullins et al, 2016).
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Providers are concerned about patient adherence to the PrEP daily medication schedule,
attendance at monitoring visits, the development of viral resistance due to incomplete adherence,
participation in behavioral interventions such as counseling or group work, side effects of the
medication, toxicity (e.g. effects on bone density and renal function), and financial difficulties
(Mullins et al, 2015). These concerns were identified as common barriers to PrEP prescription.
Perceived high cost of insurance was associated with reduced intention to prescribe PrEP to
AYA (Mullins et al, 2016). There is also a concern about risk compensation: the possibility that
patients might participate in riskier behaviors since they felt protected from HIV infection
because they utilize PrEP (Mullins et al, 2016). Some prescribers are concerned about negative
publicity and the negative attitudes of colleagues toward PrEP, particularly in prescribing PrEP
to patients who are below 18 years of age (Mullins et al).
Willingness to Prescribe PrEP. The CDC guidelines recommend PrEP for those who
have ongoing high risk of HIV acquisition and are able to metabolize prophylactic medications,
(indicated by a creatinine clearance greater than or equal to 60 mL per minute) (CDC, 2012).
Women at high risk for HIV are considered appropriate for the drug if they are not breastfeeding.
Those who are at high risk such as men having sex with men (MSM), having multiple sex
partners, or not using condoms are good candidates for PrEP. Clinicians in general were aware of
the CDC interim guidelines on PrEP; however, some practices diverged from the guidelines, and
clinicians attempted to construct their own operational definition of who qualify for PrEP based
on the patients that they encounter in their practice (Mullins et al, 2015).
Mullins et al (2015), found that almost all clinicians (80%) were willing to prescribe
PrEP for those who are long-term partners of persons living with HIV. Among clinicians, at least
60% were also willing to prescribe PrEP for those engaged as sex workers. Of the 162 providers
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across the U.S. who participated in the study willingness to prescribe PrEP was strongly
associated with the belief that providers had enough knowledge to safely provide PrEP to
adolescents and young adults (Hart-Cooper, et al, 2018). Although almost all providers agreed
that PrEP prevents HIV, not all were willing to prescribe PrEP to young adults (77.8%) and even
few willing to prescribe to adolescents (64.8%). A history of prescribing non-occupational postexposure prophylaxis (nPEP) was associated with actual prescription of PrEP (Mullins et al,
2017). Post-exposure prophylaxis is HIV preventive medication given within 72 hours after HIV
exposure such as sexual contact.
Clinicians felt that engaging in unsafe sexual behaviors (MSM, transgender, and highrisk heterosexuals) does not automatically warrant PrEP prescription, although these factors do
trigger an assessment for PrEP. Providers described characteristics of people who would not be
appropriate for PrEP, including those with: 1) the presence of a mental health diagnosis, and/or
2) substance abuse issues (Mullins et al, 2017). These presentations are also perceived as
indicators of a person engaging in higher risk sexual behavior, but with major issues likely to
negatively impact adherence to PrEP.
Barriers in Adolescents and Young Adults to PrEP Preventive Services
A summary of the barriers to AYA PrEP use from the AYA patient perspective is
demonstrated in Table 2 (Appendix B). The five studies included in the review looked at the
awareness of PrEP among AYA, their attitudes toward PrEP, social behavioral influences,
likelihood to participate in a PrEP adherence study, willingness to take PrEP, safety and
implementation issues, and adherence. More than 500 participants were included in these studies,
which include AYMSM, and transgender male and female adolescents.
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Lack of PrEP awareness. In a study of male adolescents and young males who have sex
with men by Perez-Figueroa et al (2015) revealed that approximately 50% have an awareness of
PrEP. Some compared taking PrEP to taking birth control (a form of medication that prevents an
unwanted outcome with just a pill a day). For others, the consistency required by a PrEP regimen
could be problematic. Consequently, despite of the awareness of PrEP, study participants
expressed hesitation about PrEP use. AYMSM desired more information about PrEP including
side effects, various types of drug regimens, active ingredients in the medications, and the odds
of contracting HIV while on PrEP (Perez-Figueroa et al). In transgender male and female AYA,
half of the study respondents indicated they would probably participate in a PrEP adherence
study (Fisher et al, 2017). In the study of Holloway et al (2017), the willingness to take PrEP
among AYMSM is significantly associated with the time since their last HIV test, their level of
concern about becoming infected with HIV, recent receptive condomless anal sex, the use of
illicit drugs in the past six months, and their HIV risk index score.
Negative attitudes toward PrEP. For some AYMSM, PrEP is one of several strategies
to protect themselves from acquiring HIV other than condoms. However, they viewed taking
daily medication as harder to remember than using condoms (Perez-Figueroa et al, 2015). In a
transgender study (Fisher et al, 2017), a quarter (23%) did not want to add another medication to
their health regime. Regardless of age and gender, about half of participants were extremely
worried about the negative side effects of PrEP. One-third were concerned about getting to
quarterly appointments (Fisher et al). Likewise, increased medical mistrust was associated with
decreased willingness to take PrEP among AYMSM (Holloway et al, 2017). However, not all
adolescents and young males who have sex with men are concern about getting HIV. YMSM
less concerned about the risk of getting HIV were twice as unlikely to be willing to take PrEP as
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compared to YMSM who had medium or high concern of acquiring the infection (Holloway et
al).
Economics. Taking PrEP medications entails financial burden, particularly for those who
have no insurance or have no access to PrEP subsidy programs. Young men of color often voiced
concerns about the cost of PrEP (Holloway et al, 2017).
Adherence and retention. For some, the consistency required by a PrEP regimen could
be problematic. They viewed taking daily medication as harder to remember than using condoms
(Perez-Figueroa et al, 2015). One-third were concerned about getting to quarterly appointments
(Fisher et al). Adherence to PrEP is viewed by AYMSM as difficult in the long term. AYA were
concerned about missing pills, developing resistance to PrEP, and contracting HIV, as well as
side effects (Perez-Figueroa et al, 2015). Greater concern about adherence was associated with
decreased willingness to take PrEP in AYMSM (Holloway et al, 2017). In a measure of
adherence study among youth in PrEP by Koss et al (2018), adherence to PrEP use waned over
time in AYA, particularly after week 12. Self-reporting in a PrEP protocol overestimates actual
adherence by young people (Koss et al). The most common reasons for missing doses of PrEP
were: 1) being away from home; 2) being too busy; 3) forgetting; and 4) changes in routine
(Hosek et al, 2017).
The stigma of PrEP. In general, stigma towards HIV is a barrier to HIV prevention and
PrEP is not an exception. Some AYMSM viewed PrEP negatively as a preventive strategy for
those who engage in high-risk sexual behaviors or more frequent casual encounters (PerezFigueroa et al, 2015). Use of PrEP was viewed as a trust and fidelity issue, i.e. taking PrEP could
mean the likelihood that the individual will have sex outside the primary relationship (PerezFigueroa et al, 2015). However, some reasoned that if their partners were having sex outside of
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the relationship, PrEP could serve as a protection (Perez-Figueroa et al). Holloway et al (2017)
reveals that YMSM who were unwilling to take PrEP had concerns about stigma, in addition to
questions about drug effects, risk compensation, medical mistrust, adherence, access, and
affordability. Increased medical mistrust was associated with decreased willingness to take PrEP
in AYMSM (Holloway et al, 2017). Other participants questioned the necessity of taking PrEP.
Other barriers. Not all adolescents and young males who have sex with men show
concern about getting HIV. YMSM less concerned about the risk of getting HIV were twice as
unlikely to be willing to take PrEP as compared to YMSM who had medium or high concern that
they might acquiring the infection (Holloway et al, 2017). Other participants questioned the
necessity of taking PrEP. The willingness to take PrEP among AYMSM is significantly
associated with the time since their last HIV test, their level of concern about becoming infected
with HIV, recent receptive condomless anal sex, the use of illicit drugs in the past six months,
and their HIV risk index score Holloway et al, 2017).
Rationale
The focus of this project was preventative health services, specifically in
community and public health organizations targeting underserved populations. Creating
an adolescent-friendly primary care environment that makes PrEP available to
adolescents and young adults at risk can reduce barriers to effective HIV prevention . The
goal is to minimize, if not eliminate, new HIV infections in this cohort in San Francisco
through a comprehensive educational package of PrEP and HIV prevention.
Working with the Community Health Programs for Youth in the SFDPH, the AYA
ComPrEP was designed to create a PrEP program for Balboa Teen Clinic by enhancing
and standardizing CHPY’s PrEP provision practices, existing PrEP guidelines, and
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adopting them for Balboa. To support clinician services, the project includes a needs
assessment and training workshop on recent HIV research and guidelines, the
development of an HIV-risk screening tool, templates for the electronic health record
(EHR), and PrEP management protocol, as well as web-based and hard copy resources for
providers and staff. The objective was to conduct an education and training session to
increase confidence for medication prescription and counseling for PrEP/HIV in
clinicians and staff to increase PrEP utilization and uptake in the appropriate at risk
patients.
Conceptual Framework
Two models, one the Diffusion of Innovation theory and the other, Awareness
Adherence model, were applied to increase PrEP initiation and prescription at CHPY.
The theory of diffusion of innovation by Everett Rogers originated in the field of
communication to explain how an idea or product gains momentum and diffuses
through a specific population or social system (Kaminski, 2011). The Awareness to
Adherence Model (AAM) also focuses on change, positing that any shift in mindset is
dependent on the following steps: awareness, agreement, adoption, and adherence (Freed,
Pathman, Konrad, Freeman, & Clark, 1998).
These two models, when applied to the AYA ComPrEP Project, represented
various processes that aided in implementing this protocol. The awareness adherence
model was useful in identifying ways to improve clinicians and staff members’ adherence to
PrEP guidelines by demonstrating where clinicians and staff fell off the path to adherence, and
when they were at greatest risk for not attaining each step in the clinical protocols. An initial
gap assessment looked at factors associated with a greater likelihood of attaining the steps
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ComPrEP would increase awareness of PrEP clinical practice guidelines through education
and training for clinicians. Training reviewed HIV-risk identification and the specifics of the
HIV-risk screening protocol. Understanding the rationale and benefits of making robust PrEP
services available to adolescents and young adults, clinicians and staff would more likely to
follow the new HIV-risk screening protocol. Over time, the goal was that this program,
AYA ComPrEP, would be disseminated among clinicians, staff members and its
patients (adolescent and young adults) until a saturation point is reached, and the
majority of staff and patients adopted the new practice as status quo.
One of the goals of AYA ComPrEP was to provide effective, standardized services and
then document what was most successful in this model so it could be scaled and applied in
other communities, initially in the San Francisco Bay Area. The AYA ComPrEP would be a
well-timed initiative if State of California funding is secured for PrEP provision.
Specific Aims
The overall goal of the AYA ComPrEP Project was to improve HIV prevention in
adolescents and young adults (AYA) by preparing clinicians and/or clinic staff to confidently
provide PrEP services to this populations (Appendix C). The interventions were designed to
increase clinician and clinic staff identification of AYA with substantial HIV risk and create
an education platform on PrEP targeting the needs of AYA. Specifically, it was projected
that by April 2020, clinicians and clinic staff who participated in the training
workshops would have increased knowledge and comfort to prescribe PrEP
demonstrated by at least 80% of the clinicians with increased knowledge score in post-
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training and verbalization of comfort and readiness to provide PrEP and HIV
preventions services to at-risk adolescents and young adults.
Stakeholders
Stakeholders for the AYA ComPrEP Project included the leadership, providers, staff, and
patients of CHPY, their partner agencies including non-government organizations, and other
clinicians and primary care providers and staff who maybe interested about PrEP services for
AYA. The partner agency of Balboa Teen Clinic includes the Balboa High School of the San
Francisco Unified School District (SFUSD), which the clinic is located. A complete list of
CHPY clinics is shown in Appendix D. Through partnership and collaboration, CHPY is tasked
to take the lead in providing HIV prevention services for AYA in San Francisco and contribute
to the achievement of the SFDPH’s mission in the ‘Getting to Zero’ initiative. Other stakeholders
are the public health and local health clinics, as well as public and private organizations working
for the health of adolescents and young adults. Pharmaceutical companies, particularly Gilead
(the maker of Truvada™ and Descovy™), may also be interested in this project, since they have
a history of support for projects related to PrEP.
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Section III--Methods
Gap Analysis & Needs Assessment Results
Upon consultation with CHPY leadership, the author received permission to conduct this
project at CHPY (Appendix E). After the development of the project proposal, the author
performed a gap analysis by observing clinical practice, reviewing existing clinical data on PrEP,
and staff interviews. Within San Francisco, PrEP is currently offered in two clinics of CHPY: 1)
Cole Street Clinic, and 2) Larkin Street Clinic. It is not offered at Balboa Teen Health Center
where the project was implemented. Based on clinical observations at both Cole and Larkin,
standardization for HIV prevention is lacking, particularly in the identification of at-risk PrEP
candidates. Based on an initial review of the CHPY intake form in the electronic health record
and staff interviews, it appears that there are currently no patient inquiries related to PrEP use or
PrEP prescription during initial intake.
While the STI screening template is available in the electronic health record (e.g. a series
of screening questions asking for the number of sexual partners of patients, use of condoms, and
STI symptoms), there is no standardized template that specifically prompts clinicians to analyze
HIV risk and initiate PrEP counseling or intervention. To increase PrEP prescription, a standard
assessment template is needed in the electronic record that CHPY clinicians use to do risk
assessment and identify PrEP candidates. Sexual history and other risk behavior assessments are
also being performed inconsistently. Currently, initiation and prescription of PrEP is merely
based on the clinician’s individual judgment or preference, or whether the patient requests PrEP.
There are times when clinicians feel so uncertain of the guidelines and policy they call other
clinicians assigned at other clinics to consult on whether to prescribe PrEP. This is a time-
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consuming process that can be avoided if training for clinicians and staff is regularly done, and
more standardized screening tools, templates, and protocol are implemented.
While data on PrEP prescriptions at CHPY clinics was generated through the electronic
health record and followed by the SFDPH PrEP monitoring group, the majority of clinic staff
and providers at CHPY have not seen the specific research findings and data on PrEP reduction
of HIV infection. There is also the need for clinic staff to understand the data and analyses of
PrEP prescription at CHPY to track and improve its clinical practices on HIV prevention for
AYA. It is estimated by CHPY that of all its patients who are started on PrEP, around 30% of
them discontinue taking PrEP without follow-up. Based on chart reviews of some CHPY
patients, not all patients who tested for sexually transmitted infections such as gonorrhea and
chlamydia are screened for PrEP, particularly heterosexual AYA patients. A significant gap
exists between the number of at-risk patients who qualify for PrEP and the number of these
patients who were actually offered PrEP. The initial gap assessment revealed lack of
continuation of PrEP after implementation, lack of follow-up for those who discontinued PrEP,
and in specific cases, conversion of adolescents to HIV positive.
Upon consultations with CHPY Leadership and PrEP Champion, it was decided that
rolling out PrEP at the 3rd biggest clinic of CHPY, The Balboa Teen Clinic, would be more
beneficial for CHPY and the adolescents of San Francisco who may benefit from PrEP. A needs
assessment through in-depth interviews was suggested and carried out. Tools such as the Project
Information for In-Depth Interview Participant (Appendix F) and the In-Depth Interview
Questionnaire (Appendix G) were developed for the needs assessment.
According to the results of in-deep interviews (Appendix H) and gap analysis, it was
determined that CHPY would benefit from the implementation of the AYA ComPrEP Project,
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which focused on education or training of clinicians and staff on PrEP. In-deep interviews
among nine staff of the Balboa Teen Center were conducted from December 12, 2019 to January
30, 2020. The result of the in-depth interviews revealed the following themes or issues related to
making PrEP services available in the clinic:
1. All participants want to have PrEP services available at Balboa Teen Health Center.
Everyone is excited about it. The thought that this will be the first school-based PrEP in
California (one of the firsts in the United States and countries in the world) excites the
team;
2. Each team member has a role to take in this initiative. There is a need to clarify or
communicate roles. Everyone is willing to participate;
3. Staff members need education, training, and workshop both for first timer and as a
refresher for those who had a PrEP training previously before seeing patients in the clinic
for PrEP outreach, education/counseling and PrEP prescription;
4. Clinic members voiced the need for materials on PrEP, including presentation materials
about PrEP for AYA for teachers, staff, students, and patients.
5. All interviewees pointed that the clinic need good outreach and dissemination strategies
to reach communities and potential patients of PrEP services in Balboa.
GAANT
The AYA ComPrEP Project implementation took place from September 2019 to April
2020 (Appendix I). Since 2018, the author had planned the project with DNP Chair, Dr. Prabjot
Sandhu and DNP committee member Dr. Stefan Rowniak. Approval for the project with the
CHPY leadership: Dr. Lori Kohler (Medical Director), Carol Tanuguchi, NP (Clinical Nurse
Lead), and Adam Leonard, NP (PrEP Champion at CHPY) was given in September 2019.
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Earlier, starting May 2018, the author initiated this project topic after researching the evidencebased literature on barriers to PrEP in AYA. A brief gap analysis of CHPY’s PrEP
implementation practice has been done followed by needs assessment. Conducting the needs
assessment revalidated the gap analysis. February through November 2019 have been spent on
the initial planning for AYA ComPrEP, which has included consultation with experts and staff,
review of literature, and exploration of guidelines, screening tools and templates. The second
milestone, in-depth interviews with Balboa Teen Health Center was completed on December to
January 2020. PrEP manual and binder were created, and modules for training workshops on
AYA and PrEP were developed from December to March 2020.
Subsequently, in a third phase, the education piece, the training and workshop was
conducted in April 2020. However, in light of COVID-19, with the closing of the Balboa Teen
Health Center, an online simulation for clinicians (NP students) of the University of San
Francisco. The scheduled training and workshop for Balboa clinicians and staff on March 13,
2020 was cancelled due to the closure of the clinic related to the ‘shelter in place’ policy in
placed as a measure against the COVID-19 pandemic. The fourth and final milestone, evaluation
of the intervention and its measurable outcomes was completed by the end of April 2020.
Dissemination of the results took place by May 2020 and onwards.
Responsibility/communication plan. Planning for the AYA ComPrEP Project required
interdisciplinary responsibility and continuous communication (see Appendix J for the work
breakdown and Appendix K for the communication plan).
The interprofessional collaboration for this project had occurred primarily among the
author, Adam Leonard, NP, Carol Taniguchi, NP, and Dr. Lori Kohler of CHPY, and the
author’s DNP committee advisers, Dr. Sandhu and Dr. Rowniak. Working directly with Carol
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and Lori, the author was responsible for the development, implementation, management, and
evaluation of the project. Carol and Lori lead the CHPY program, serving as clinical experts on
CHPY’s patient population, and on HIV prevention. As CHPY’s lead director and nurse
practitioner, they have provided authorization for the AYA ComPrEP project and potential
changes to clinical practice on site. Adam Leonard, NP was CHPY’s Champion on PrEP having
had experiences on PrEP prescribing and being the clinician who initiated PrEP services at Cole
Street Clinic and Larkin Street Clinic. He met with the project author multiple times, provided
gaps, information, guidance of the project within CHPY, and recommended Balboa Clinic as the
implementing site. Dr. Sandhua and Dr. Rowniak provided feedback and guidance all throughout
the planning, implementation, and evaluation phases of the project, including the approval of the
online simulation training for clinicians of USF.
SWOT Analysis
The following SWOT analysis describes the project’s strengths, weaknesses,
opportunities, and threats in relation to CHPY that have the potential to affect its implementation
(Appendix L).
Strengths. CHPY is the youth arm of the San Francisco Department of Public Health,
serving adolescents and young adults. It is a smaller program in a bigger public health
organization that has three team leaders, which makes managing the bureaucracy easier. CHPY
is comprised of more than ten major and satellite specialty clinics across San Francisco. It
provides comprehensive clinical services for adolescents and young adults (AYA) ages 12-25,
including those who are transgender and homeless (SFHN, 2018). CHPY nurtures an
environment that is compassionate and sensitive to its patients’ culture and beliefs. It provides
primary care and reproductive health services to all AYA regardless of their socio-economic
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status. Both the patient population and CHPY staff members share similar backgrounds as
LGBTQ community members and/or people of color, producing a trusting environment that is
open to change for improvement. The Family Planning program (FPACT) of the State of
California reimburses CHPY clinics for family planning services, which could cover PrEP.
CHPY also has an emergency fund for patients who have no insurance, which could additionally
cover PrEP medication. This funding would address a vital need, given that CHPY’s patients
represent an at-risk AYA population that qualifies for PrEP. Given the magnitude of this need, a
DNP project focused on youth and young adults at risk of HIV infection is appropriate and
relevant. The agency’s strengths support the project’s potential to improve PrEP clinical
implementation for AYA patients.
Weaknesses. CHPY has been through a great many changes in the past two years,
including disruptive events such as staff resignation and transfers to other departments. CHPY
recently lost two of its three nurses, who were well trained in screening for PrEP. Towards the
last quarter of 2020, one of the clinicians of CHPY who started PrEP at Larkin and Cole clinics
also resigned. Despite being a part of the wider SF Health network, some clinicians of CHPY are
not clear of the protocol on PrEP specifically for AYA. There is also a need for clinicians to
update about the specifics of the PrEP medications available and when to use them. The new
EHR system represents another challenge, because of the new transition from eCW to Epic, it
was expected that there would be limitation to capture clinical data. Difficulty navigating the
former EHR (eCW) posed problems in this DNP project during the baseline assessment and
evaluation. Therefore, project implementation could face difficulties with technology and
adherence to change in practice.
Opportunities. CHPY is part of the broader SFDPH, which could provide access to
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funding and opportunities for additional support. SFDPH is known for its competency in
providing quality HIV prevention and management interventions, particularly to key populations.
CHPY is also a part of the recent Getting to Zero initiative for San Francisco, focusing on young
people. Currently, one-third of new HIV infections are among young people ages 12 to 24,
making it strategic for CHPY to strengthen its PrEP program in order to be proactive in HIV
prevention in San Francisco. The announcement of FDA approval for Truvada use as PrEP for
young people below 18 years of age will make the medication more acceptable to clinicians.
Threats. Obstacles to PrEP use include patient refusal of the medication due to lack of
awareness of its effectiveness, negative attitudes toward PrEP, economics, lower adherence and
retention rates, relationship status, and stigma. Taking PrEP medications entails financial burden,
particularly for those who have no insurance or have no access to PrEP subsidy programs. In a
study of AYMSM by Holloway et al (2017), young men of color often voiced concerns about the
cost of PrEP. While some health insurance plans such as Medi-Cal cover the entire cost of PrEP,
others do not. Adherence to PrEP is viewed by AYMSM as difficult in the long term. AYA were
concerned about missing pills, developing resistance to PrEP, and contracting HIV (PerezFigueroa et al, 2015). Regardless of age or gender, about half of participants interviewed in one
study were extremely worried about the negative side effects of PrEP (Fisher et al, 2017).
Another of the barriers to PrEP uptake is cultural stigma, which stems from pre-existing
attitudes toward HIV, and specifically depicts patients taking PrEP as “Truvada whores.” Yet the
perception of low HIV-risk is the primary reasons AYA decline PrEP, representing an
individual-level barrier to PrEP uptake. For these reasons an identified at-risk patient may refuse
PrEP evaluation, and an eligible patient may refuse to initiate PrEP. Such threats could affect the
PrEP implementation cascade, and subsequently, this project’s measurable outcomes.
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Budget and Cost Benefit Analysis
This project was implemented without financial cost to CHPY by utilizing available
resources within SFDPH, its networks, and partner agencies. The author absorbed the majority of
the project’s cost as an unpaid resource responsible for project development and management.
Some cost of this project was taken from the Jonas Scholarship fund that was received by the
author. The cost of implementing the project was $660 (Appendix M), which consists of
materials developed and used for AYA ComPrEP folders and binders Going forward, for Balboa
Teen Clinic, one staff member such as a nurse, medical assistant, or a person from the partner
non-profit organization should function as a PrEP coordinator, comparable to a vaccine
coordinator, such as a nurse or medical assistant. This work is already part of staff duties, and
would simply be more clearly defined. Consequently, this role would not entail increased salary
costs, so it is not included in the project budget.
By preventing HIV infection, this DNP project produces a significant benefit of costavoidance and savings in HIV management (Appendix N). HIV antiretroviral treatment costs
approximately $20,000 and upwards per patient per year (CDC, 2015). The cost of PrEP
pharmacotherapy is $13,000 per patient per year. If all of CHPY’s suspected at-risk patients
acquired HIV and required antiretroviral treatment, that would entail significant resources,
minimally $20,000 annually per person. When patients are started on PrEP and HIV infection is
prevented, an estimated $7,000 in costs per patient are avoided each year. By expanding PrEP
implementation, this project also produces a return on investment (ROI) unique to CHPY in the
form of increased health insurance reimbursements. CHPY qualifies for Medi-Cal and Family
Planning reimbursement. It is important to clarify that initiating PrEP for established Medi-Cal
patients does not create additional reimbursement. However, PrEP treatment does require
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frequent follow-up, which would keep patients in care, contributing to patient retention, and thus
reimbursement (Appendix I). Other than the financial benefits, there are benefits related to
quality of life, decreased stigma, decreased suicide rates in this population, and increased access
to prevention services for most-at-risk populations. HIV prevention strategies that include PrEP
are beneficial for most at-risk populations than allowing them to get infected and then later have
them on HIV disease management.
Pre-Implementation Intervention
Screening Tool Development. Prior to the implementation of the project, the
development of screening tools was done. This initial phase of the project included the
revision and adoption of existing STI screening tools of CHPY to include screening for risk of
HIV infection. The screening tool was based on available risk assessments such as the Clinical
Practice Guidelines of the CDC, guidelines from the WHO, the California Department of Public
Health (CDPH), the SFDPH, and the PrEP Education for Youth-Serving Primary Care Providers
Toolkit developed by the Sexuality Information and Education Council of the United States
(SIECUS). They are available online but have to be reviewed and tailored to the needs of the
AYA populations.
•

Performance of a gap analysis. An assessment was performed to determine what
type of screening tools are currently used for PrEP, HIV, and STI assessments.

•

Selection of optimal screening tool. The most appropriate tool was selected after the
need was clearly established. Tools that were used in this project included the Quick
Clinical Guide: HIV PrEP developed by the AIDS Education & Training Center
(Appendix O), and the Ask about PrEP (Appendix P) of the San Francisco
Department of Public Health.
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Development of a screening tool, if necessary. The tools recommended by the
CDC, the WHO, CDPH, SFFDPH, and SIECUS meet the needs of health care
delivery to adolescents at Balboa Teen Clinic. The WHO tool was adopted for
screening of risk (Appendix Q).

•

Establishing the screening protocol. A model screening protocol and algorithm for
offering PrEP to patients was adopted and developed by reviewing current policy and
clinical nursing algorithms, evidence-based practice, and the recommendations of
PrEP experts, clinicians, and staff. The algorithm of the SFDPH was adopted.

•

Integrating risk assessment into existing STI screening. These inquiries could be
integrated into the electronic health record (EHR) but was not done due to the
limitation as a result of the COVID-19 pandemic. However, a one-page laminated
Clinical PrEP essentials developed by SFDPH for providers is available for use
(Appendix P). Relevant questions relate to sexual preference and practices, potential
HIV exposure, and STI status is also developed.

In a setting such as the Balboa Teen Clinic, as adolescent patients are roomed, clinic staff
(nurses, medical assistants, and health workers) are expected to competently use the AYA
ComPrEP screening tools to assess for HIV risk. This provides an opportunity to offer
information to each new patient on sexually transmitted infections including HIV and AIDS, as
well as STI testing, and prevention strategies including PrEP. Clinic staff should be able to
identify at-risk AYA and communicate that risk to the clinician.
Implementation
The AYA ComPrEP was designed as a HIV-prevention program utilizing PrEP, developed
for the San Francisco agency, Community Health Programs for Youth. The program integrated
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the biomedical and AIDS risk-reduction models to optimize PrEP intake among adolescents and
young adults. The project was implemented in three phases:
1) Education of staff or clinicians
2) The use of the screening tools and protocol integrated into the workflow or the EHR
system
3) Evaluation of the AYA ComPrEP Project
Part 1. Clinicians and Clinic Staff Training and Seminar
The education piece for clinicians was done online via Zoom conference. The author with
the guidance of Dr. Sandhu created a training agenda (Appendix R) and four modules for the
online training presentation.
1.1 Providing vital updates on HIV and PrEP. Clinical content were drawn from
public health information of the WHO, CDC, CDPH, SFDPH, and SIECUS.
•

Module 1 covered the basic of sexually transmitted infections and HIV & AIDS
(Appendix S), while module 2 discussed about the key elements of HIV counseling
(Appendix T).

•

Discussion included a series of relevant facts about adolescents motivating providers
to provide youth-friendly services, which include a review and understanding the
realities of young people, their reproductive health, and the SOGI initiative for
module 3 (Appendix U).

•

FDA recommendations for PrEP, summaries on the safety of the newest PrEP drugs,
which have reduced toxicity and therefore less risk to liver and kidney health, and
alternate dosing protocol, which also reduce the amount of drug required and
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therefore the level of toxicity and potential side effects were covered on Module 4:
Pre-Exposure Prophylaxis Appendix V).
1.2 Switching the focus of the training. Two separate training workshops were first
suggested for the clinician and staff of Balboa Clinic but then later changed to be a jointseminar. The face-to-face seminar at Balboa Teen Clinic was scheduled but was
cancelled due to the COVID-19 pandemic. As an alternate, an online simulation was
done for clinician trainees of USF. This online seminar aimed to increase the comfort
level and ease with which providers initiate and prescribe PrEP to AYA who are at highrisk of HIV infection.
1.3 Developing additional professional materials. In addition to the seminars, the
author created information packets in a pocket folder, complete with index tabs, so
clinicians can quickly access Q & A summaries from the literature on effectiveness rates,
alternate dosing protocol, side effects, insurance, financial support, and other potential
concerns.
Part 2. Patient Education and Motivation. This intervention has not happened yet due to the
closure of the school and clinic related to the COVID-19 pandemic.
2.1 Supporting patient self-care. The decision to take PrEP may be attributed to
patients’ recognition of their risks, making a commitment to reduce high-risk sexual
contacts, and to increase low-risk activities. Those at high risk for HIV will be offered the
option of enrolling in a PrEP program, and staying in contact with a health care
environment where they have access to reproductive and sexual health services.
2.2 Providing patients with the most current information.
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Regarding permission to prescribe, many adolescent patients are unaware that
they are now legally empowered to obtain PrEP with total confidentiality, and
without their parent’s consent or knowledge.

•

Concern over toxicity is another reasonable objection raised by young patients, so
relevant information will be included on the most recent form of PrEP with lower
toxicity, as well as alternate dosing schedules that reduce the amount of the drug
required.

2.3 Engaging patients with age-appropriate materials. The author has observed how
motivating the use of Quit Smoking kits have been in the CHPY clinics. Using this
program as a model, ComPrEP kits will be designed especially with youth in mind. These
are bags that contain freebies, condoms, and educational materials on PrEP and HIV
prevention similar to the Quit Smoking Kits currently distributed by the San Francisco
Department of Public Health.
Part 4. PrEP Protocol Implementation and Evaluation
Implementation of the HIV screening tools and PrEP protocol will be integrated into the
electronic health records of CHPY and demonstrated in the seminars. Use of the screening tool
and protocols can begin immediately, on completion of the training. Following the seminars,
personnel will receive an assessment of the training, which will include open-ended questions on
possible improvements. A follow-up assessment will also be performed 6-8 weeks after the
training and seminars.
Study of the Methods
After launching the education piece of the AYA ComPrEP, which methods statistical,
analytical, qualitative? Etc. for evaluating the effectiveness of the online training and workshop
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and simulation to implement the use of PrEP guidelines and screening protocol were performed.
In the arm of the intervention for clinicians, post-training competency a survey aimed at
assessing increased knowledge were evaluated using baseline and post-test scores. Evaluation of
clinicians’ comprehension and comfort to initiate dialogue and prescribe PrEP was performed
through the post-training evaluation. Each participant was asked to submit a plan for changes in
practice were asked at the end of the training. This data can be used to re-assess the impact of the
project in the routine utilization of the HIV PrEP screening tool and the established screening
process in their practice.
Outcome Measures
Primary outcomes. Initially, the primary intent of the project was that by the end of
April 2020, the Balboa Teen Clinic will have integrated the AYA ComPrEP program into
their practice, offering PrEP services to its patients looking at the percentages in
knowledge increase, the use of guidelines, and satisfaction with the implementation of the
new risk assessment and the PrEP protocol by clinicians and staff in their practice. However,
due to closure of the school and the clinic, the primary outcomes were limited to conduct
of the online training and workshop for the clinicians of the University of San Francisco.
These outcomes can be used as a basis for recommendations for training and seminar on
PrEP for AYA for other clinic and for Balboa Clinic when it opens in the future. The
following modified primary outcomes were used to evaluate the effectiveness of AYA ComPrEP
Project, based on improvement from baseline clinical practice and outcomes (Appendix G):
•

Clinicians at CHPY and the University of San Francisco are well recognized
for their training, expertise, and willingness to learn. In this context , it is
projected that as many as 80% of the clinicians who attended the training
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workshop will have increased knowledge on HIV and PrEP demonstrated by
achieving at least 80% passing rate on the training knowledge competency
evaluation;
•

At least 80% of the clinicians who attend the training workshop will have
increased in enabling or non-stigmatizing attitudes on HIV and PrEP;

•

At least 80% of the providers will use the guidelines (e.g. risk assessment tool and
protocol) in practice demonstrated in the case studies simulation; and

•

At least 80% of the clinicians will state increased comfort in prescribing PrEP
to AYA patients after the simulation.
Analysis

Quantitative and qualitative analytical methods were used for the evaluation of the AYA
ComPrEP Project such as descriptive statistics that provide the demographics of clinicians and
staff who participated in the intervention. Evaluation tools were developed to gather data for
analysis of outcomes using the Likert Scale, a psychometric measure widely applied in survey
research. Evaluation tools included pre- and post-training survey questionnaires consisting of
knowledge and attitude statements, and structured and close-ended questions.
Data Instruments and Measurement.
The questionnaires (Appendix M) used for in-depth interviews and simulation trainingworkshop consisted of structured mixed multiple choices, true or false, and close-ended
questions. The development of the instruments was based on review of literature and inputs from
the CHPY leadership, CHPY PrEP Champion, and the DNP committee of the investigator who
have expertise on developing survey questionnaires for analysis. Instruments used were designed
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specifically for this project. The participants of the in-depth interviews and pre-and postsimulation surveys were encouraged to ask questions to clarify any instructions. Data from the
in-depths interviews were used to identify gaps, challenges, and recommendations by Balboa
Teen Clinic staff on PrEP program implementation (the author planned to write a separate
manuscript on the results of the in-depth interviews). The results of the pre-and post-training
workshop were used as the intended outcome of this project, which focused on education of the
clinician trainees of USF (nurse practitioners). The pre- and post-simulation questionnaires asked
for information about:
Socio-demographic and Background Information. This short section asked about the
DNP track, year of birth, gender, and sexual orientation of the clinician participants.
HIV and PrEP Knowledge. This section was used to analyze the change in knowledge
scores of clinicians after attending the training workshop in compared to the baseline. The 22item true or false knowledge questionnaire asked mainly about HIV transmission, prevention,
and the use of pre-exposure prophylaxis (PrEP). Each item was given equal weight in scoring.
Correct answer were scored one point while incorrect response scored zero. The possible range
of knowledge scores is 0-19.
Enabling and Non-stigmatizing Attitudes. This section was used to analyze the change
in enabling or non-stigmatizing attitude scores of providers before and after attending the
training workshop. There were 22 statements included to measure the attitude scores. Positive
statements were considered enabling or non-stigmatizing attitudes, the scores for responses were
as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0; Strongly
disagree = 0. Others were negative statements and reverse scoring were applied to these items
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when scores allotted. The higher the score, the better the enabling or non-stigmatizing attitudes
of the providers. Attitude item score below 2 is considered stigmatizing attitudes.
Data Analysis
The author of this project collected and summarized the data using the SurveyMonkey
and Excel spreadsheet. Descriptive analysis was done using the SurveyMonkey analysis built-in
program. Likewise, some data were inputted on Excel. Microsoft Excel, a long-standing software
program widely used in accounting, statistics, and the sciences, was used to analyze both the
baseline and post-intervention clinical data that were not generated or run by the SurveyMonkey.
Through SurveyMonkey and Excel, the results for each measure were calculated as percentages,
from which graphs were generated. Graphs comparing baseline and post-intervention results
revealed the effects of the educational training and seminars, and other interventions of the
project.
Ethical Considerations
Ethical considerations directly involved in the AYA ComPrEP Project include patient
privacy and potential conflicts of interest. Patient privacy was protected by strict adherence to
the guidelines of the Health Insurance Portability and Accountability Act (HIPAA). While this is
not a research project, per Institutional Review Board (IRB) guidelines, a waiver was filed.
Capturing clinical data from the electronic health records were conducted onsite at CHPY clinics
within a secure network. Patient names and personal information were excluded from the data
captured and from the analysis of the intervention.
Implications for the ethical practice of PrEP implementation in AYA in primary care are
recognized by this project. In accordance with the American Nurses Association Ethical
Standards and the Jesuit values of the University of San Francisco, the responsibilities of the
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clinician and the healthcare site were examined. Providers must educate patients and weigh the
risks versus benefits of taking PrEP to practice beneficence and non-maleficence. To practice
justice, providers must also serve as diligent patient advocates by connecting disenfranchised, atrisk AYA patients to social and medical services necessary to access PrEP. Despite wellintentioned attempts, providers must acknowledge that their efforts to provide the best HIV
prevention methods may still be blocked by forces outside of their control, such as patient
autonomy and limited access to necessary resources.
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Section IV- Results
PrEP Online Training Workshop and Simulation
Nineteen clinicians (Nurse practitioner trainees or students) from the University of San
Francisco participated in the PrEP online simulation training-workshop. Fifteen of the clinicians
were first time to attend a training-workshop on PrEP and four of them have attended a PrEPrelated activity before (Figure 1) through the San Francisco City Clinic, the San Francisco
Department of Public Health, and the California Association of Nurse Practitioner.

Figure 1. Have you attended a PrEP
training or workshop before
90.00%
80.00%
70.00%
60.00%
50.00%
Responses

40.00%
30.00%
20.00%
10.00%
0.00%
Yes

No

Knowledge on HIV and PrEP
Table 1 shows the differences in knowledge measured by the knowledge scores obtained
from the pre-test training workshop and post-training workshop. There were 22 knowledge-based
questions answerable by True or False marked 1 point for each, a total of 22 points for
knowledge score.
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Table 1. Changes in HIV and PrEP Knowledge Score, Pre & Post-Training
Lowest
Knowledge
Score

Median
Knowledge
Score

Highest
Knowledge
Score

Mean Knowledge
Score

Standard Deviation

Pre-Training
Workshop

13 (59%)

16 (73%)

18 (82%)

16 (73%)

1.54 (7%)

Post-Training
Workshop

15 (68%)

20 (91%)

21 (95%)

19 (86%)

1.76 (8%)

Knowledge-based questions on HIV and PrEP answerable by True or False.
Each question is marked as 1 point with total knowledge score = 22

The overall results for HIV and PrEP knowledge in Figure 2 shows that clinicians had an
increased in knowledge after the training workshop compared to the baseline. There is a 17.8%
increase in overall mean knowledge score post-training workshop (mean KS = 19 or 86%)
compared to that of the pre-training workshop (mean KS = 16 or 73%).
Figure 2. Changes in HIV and PrEP Knowledge Score, Pre & Post-Training

12

10
8
6

4
2
0

Pre-Test | Mean Score 16 (73%)
Post-Test | Mean Score 19
(86%)
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All clinicians had some knowledge on HIV and AIDS prevention prior to the online
training-workshop and simulation. Table 2 shows that clinicians are aware that HIV infection is
preventable (n=19). Likewise, all are aware that daily PrEP can prevent the sexual transmission
of HIV by up to 90%, and that providing condoms is essential in HIV prevention and should be
promoted even with PrEP.
Table 2. Providers’ Pre and Post-Test Knowledge Score Difference on HIV Prevention &
Condom Use
Knowledge Items

Correct Responses (%)

Prevention of HIV Infection
There is a vaccine available to prevent HIV infection. (F)

Pre-Test
18 (95)

Post-Test
17 (89)

HIV infection is curable. A person infected with HIV can
access cure at treatment clinics or hospitals. (F)
HIV is preventable. (T)

17 (89)

18 (95)

19 (100)

19 (100)

16 (84)

19 (100)

19 (100)

19 (100)

19 (100)

19 (100)

Condom Use
Using condoms can prevent HIV transmission and other
STIs. (T)
The use of condoms should be promoted to prevent HIV
infection. (T)
The use of condoms should not be promoted if a person is
on PrEP. (F)

However, the pre- and post-training surveys reveals that clinicians have lack of
knowledge about the effectiveness of PrEP to prevent HIV through vaginal sexual exposure and
injecting drug use. About 64% of the clinicians (n=12) incorrectly believe that PrEP can reduce
the risk of acquiring HIV among people who inject drugs by 30%, the same number of clinicians
that incorrectly agreed that for PrEP to be effective against HIV infection through vaginal
transmission, it should be taken continuously once daily for 7 days before engaging in
vaginal sex. PrEP is 70% effective to prevent HIV transmission through injecting drug use while
PrEP to offer protection through vaginal sex; PrEP should be taken for at least 21 days.
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Table 3. Providers’ Pre and Post-Test Knowledge Score Difference on PrEP
Knowledge Items
PrEP
For PrEP to be effective against HIV infection should be
taken once daily and should be taken continuously for 7
days before engaging in vaginal sex. (F)
Daily PrEP can reduce the risk of acquiring HIV among
people who inject drugs by 30%. (F)
There is no alternative to daily dosing of PrEP. Other PrEP
dosing is ineffective to prevent HIV transmission. (F)
Truvada is the only PrEP regimen available in the market
to prevent HIV infection so it is easy to prescribe PrEP. (F)
Heterosexual men and women are not at risk for HIV
infection and are not recommended for PrEP. (F)
Daily PrEP can prevent HIV transmission through sex for
up to more than 90%. (T)

Correct Responses (%)
Pre-Test
4 (21)

Post-Test
7 (37)

4 (21)

7 (37)

10 (53)

19 (100)

11 (58)

19 (100)

18 (95)

19 (100)

19 (100)

19 (100)

Also, another knowledge item that revealed poor understanding is the HIV transmission
related to needle stick injury. This is similar to participant’s understanding of the evidence-based
principle of U=U (Undetectable = Untransmittable), meaning people living with HIV with
undetectable viral load are considered non-infectious based on clinical studies. They are unlikely
to transfer HIV. This is a victory in the HIV response that clinicians should be highly aware of
and should be used to empower communities of people living with HIV to take their HIV
medications so not to transfer the virus to their sexual partners. Achieving and maintaining an
undetectable HIV viral load is an evidence-based practice to prevent HIV transmission.
Table 3. Providers’ Pre and Post-Test Knowledge Score Difference on HIV Prevention (Need
Stick Injury and Undetectable = Untransmittable)
Knowledge Items

Correct Responses (%)

HIV Transmission: Needle Prick

Pre-Test

Post-Test

After needle prick injury with a needle from an HIV-infected
patient, immediately gently expressing blood from the puncture
site reduces the risk of contracting HIV infection. (T)

9 (47)

11 (58)
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After needle prick injury with a needle from an HIV-infected
person, the chance of contracting HIV is less than 1%. (T)
After a needle prick injury with a needle from an HIV-infected
person, a health worker may take HIV medications to reduce the
chance of contracting HIV infection. (T)
HIV Transmission: Undetectable = Untransmittable

13 (68)

17 (89)

16 (84)

18 (95)

A person with HIV who is undetectable is considered
infectious. He/she is likely to transmit the virus to his/her
partners through sexual intercourse.
A person will automatically get infected with HIV once he/she
has sexual intercourse with a person living with HIV. (F)

7 (37)

12 (63)

18 (95)

18 (95)

Other knowledge items that were incorrectly answered by clinicians include the
frequency of HIV testing for very high-risk patients. It should not be once a year per CDC and
SFDPH but every 3 months guidelines. Likewise, children born to HIV-positive women does not
equate to HIV-positive newborn or children.
Table 4. Providers’ Pre and Post-Test Knowledge Score Difference on STI, Risk, and HIV
Testing
Knowledge Items
STI, Risk, and HIV Testing
A person who is at very high risk for HIV and other STIs
should be tested once a year for HIV. (F)
One can be identified as HIV-positive by the way the
person looks (e.g. signs and symptoms like skin ulcers,
weight loss). (F)
If a person has a sexually transmitted infection (STI),
his/her chance of getting HIV is higher. (T)
A person who has no sexual partner is not at risk for HIV.
He/she should never be tested for HIV. (F)
Mother-to-Child HIV Transmission
Children born to HIV-positive women are infected with
HIV at birth. (F)

Correct Responses (%)
Pre-Test

Post-Test

0 (0)

11 (58)

17 (89)

18 (95)

18 (95)

19 (100)

17 (89)

19 (100)

15 (79)

16 (84)
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Enabling and Non-Stigmatizing Attitudes
Table 5 provides the difference in enabling or non-stigmatizing attitudes of providers
who participated in the online training-workshop. The mean enabling attitude score was 47
(78%) for the pre-training and workshop survey while the mean enabling attitude score post
training was 53 (88%). Figure 1 shows a 23.4% increase in enabling attitude score (11 points
increased).
Lowest
Enabling
Attitude
Score

Median
Enabling
Attitude
Score

Highest
Enabling
Attitude
Score

Mean
Enabling
Attitude
Score

Standard
Deviation

Pre-Training
Workshop

31 (52%)

49 (82%)

55 (92%)

47 (78%)

6 (10%)

Post-Training
Workshop

36 (60%)

55 (92%)

60 (100%)

53 (88%)

7.2 (12%)

20 Statements on HIV and PrEP issues, Total EA score = 60
Highly enabling response (strongly agree for positive statement or strongly disagree for negative
statement) was marked for 3 points
Enabling response (agree for positive statement or disagree for negative statement) was marked for
2 points
Neither agree nor disagree = 1 point
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Figure 2. Changes in Enabling or Non-Stigmatizing Attitudes, Pre & Post-Training
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Pre-TW Attitude
Score | Mean Score
47 (78%)
Post-TW Attitude
Score | Mean Score
53 (88%)
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Table 6 and 7 reveals the breakdown of items describing the providers’ enabling or nonstigmatizing attitudes before and after the online training workshop. Prior to the training
working, providers have stigmatizing (non-enabling) attitudes on 1) mandating disclosure to their
partners of people living with HIV (mean attitude score 0.3, SD=0.58), 2) not allowing
homosexuals to donate blood (mean attitude score 1.5, SD=1.31), 3) always involving parents for
those on PrEP (mean attitude score 1.5, SD=1.31), and 4) believing they have the right to know
the HIV status of patients in their practice including those that are not under their care mean
attitude score 1.8, SD=1.21).
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Table 6. Pre-Training Workshop Attitude Scores by Attitude Items

Neither
Agree nor
Disagree
-

Disagree

Strongly
Disagree

2
(11%)

16
(84%)

Mean
Attitude
Score
Score
Range
0-3
2.7
(96%)

4
(21%)

2
(11%)

3
(16%)

4
(21%)

1.5
(49%)

1.31

1
(5%)

-

3
(16%)

3
(16%)

12
(63%)

2.4
(79%)

0.96

7
(37%)

7
(37%)

4
(21%)

1
(5%)

-

0.3
(11%)

0.58

-

-

1
(5%)

6
(32%)

12
(63%)

2.6
(86%)

0.61

1
(5%)

2
(11%)

1
(5%)

4
(21%)

11
(58%)

2.2
(74%)

1.13

-

-

-

4
(21%)

15
(79%)

2.8
(93%)

0.42

4
(21%)

1
(5%)

-

7
(37%)

7
(37%)

1.8
(61%)

1.21

16
(84%)

2
(11%)

-

1
(5%)

-

2.7
(91%)

0.73

Attitude Item
Attitude of Blame &
Disclosure
In my opinion, persons
living with HIV deserve
their illness.
Homosexual men should
be allowed to donate
blood. a
People who are HIV
positive should be
encouraged to keep their
diagnosis to themselves.
A person who is HIVpositive should be
mandated to tell their
partners about their HIV
status.
People who test positive
for HIV should not
engage in any sexual
activity.
Attitude Toward Person
Living with HIV and the
workplace
I am uncomfortable
providing care for an HIV
infected person.
A person who is HIV
positive should not be
allowed to work as a
health worker.
I have the right to know
the HIV status of the
patients/clients in our
practice/unit/department,
including those who are
not under my care.
I am willing to work in the
same unit/office with a
colleague who is HIV-

Proportion (%) of Respondents
Strongly
Agree

Agree

-

1
(5%)

6
(32%)

SD

0.73
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positive. a
Health care workers
should be required for an
HIV antibody test before
engaging in any hospital
or clinical practice.
I have the right to know if
someone in our workplace
is HIV-positive.
Attitude toward PrEP
and role in HIV
prevention
As a professional health
worker, I have the duty to
educate the public on HIV
and PrEP. a
Adolescents and young
adults, including those
below 18 years of age,
who are at high-risk of
HIV infection should be
offered PrEP. a
Counseling should be a
part of any PrEP program.
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-

-

4
(21%)

7
(37%)

8
(42%)

2.2
(74%)

0.79

-

-

1
(5%)

6
(32%)

12
(63%)

2.6 (86%)

0.61

13
(68%)

5
(26%)

-

1
(5%)

-

2.6
(86%)

0.77

14
(74%)

5
(26%)

-

-

-

2.7
(91%)

0.45

15
(79%)

4
(21%)

-

-

-

2.8
(93%)

0.42

17
(89%)

2
(11%)

-

-

-

2.9
(96%)

0.32

14
(74%)

5
(26%)

-

-

-

2.7
(93%)

0.45

-

-

-

6
(32%)

13
(68%)

2.7
(89%)

0.48

9
(47%)

8
(42%)

2
(11%)

-

-

2.4
(79%)

0.68

-

-

-

2

17

2.9

0.32

a

Non-clinician staff
(nurses, medical
assistants, health workers)
should take an active role
in adolescents PrEP
follow-up and monitoring.
a

Same-Day PrEP should be
made available and
offered to adolescents atrisk for HIV. a
It is embarrassing to talk
about sex and condom use
with patients, therefore, I
should not initiate to talk
about it with them
Alternative PrEP dosing
such as event-based
dosing should be made
available to adolescents. a
Condoms are for married
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people only. Adolescents
(11%)
(89%)
(96%)
should be prohibited from
using condoms.
Parents of adolescents,
1
3
5
7
3
1.5
1.02
particularly those below
(5%)
(16%)
(26%)
(37%)
(16%)
(49%)
18 years of age, who are
on PrEP should always be
involved in their care.
Note: a Positive statements were considered enabling or non-stigmatizing attitudes, the scores for
responses were as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0;
Strongly disagree = 0.
Others were negative statements, reverse scoring were applied to these items when scores allotted.
Attitude item score below 2 is considered stigmatizing attitudes.

The result on Table 6 revealed that despite the model of online training versus in person
training, there was an increase in enabling attitude scores, some providers remain to have
stigmatizing or non-enabling attitudes on HIV issues such as mandating a person who is HIV
positive to tell their partners about their HIV status, lowest attitude score of 1.3, SD=1.38.
Likewise, attitude towards allowing homosexual to donate blood received the second lowest
average attitude score, 2.1, SD=1.13.

Table 6. Post-Training Workshop Attitude Scores by Attitude Items
Attitude Item

Attitude of Blame &
Disclosure
In my opinion, persons living
with HIV deserve their
illness.
Homosexual men should be
allowed to donate blood. a
People who are HIV positive
should be encouraged to

Proportion (%) of Respondents

Strongly
Agree

Agree

-

-

9
(47%)
-

5
(26%)
-

Neither
Agree nor
Disagree
-

Disagree

Strongly
Disagree

2
(11%)

17
(89%)

Mean
Attitude
Score
Score
Range
0-3
2.9
(96%)

2
(11%)
1
(5%)

1
(5%)
4
(21%)

2
(11%)
14
(74%)

2.1
(68%)
2.7
(89%)

SD

0.32

1.13
0.58
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keep their diagnosis to
themselves.
A person who is HIVpositive should be mandated
to tell their partners about
their HIV status.
People who test positive for
HIV should not engage in
any sexual activity.
Attitude Toward Person
Living with HIV and the
workplace
I am uncomfortable
providing care for an HIV
infected person.
A person who is HIV
positive should not be
allowed to work as a health
worker.
I have the right to know the
HIV status of the
patients/clients in our
practice/unit/department,
including those who are not
under my care.
I am willing to work in the
same unit/office with a
colleague who is HIVpositive. a
Health care workers should
be required for an HIV
antibody test before
engaging in any hospital or
clinical practice.
I have the right to know if
someone in our workplace is
HIV-positive.
Attitude toward PrEP and
role in HIV prevention
As a professional health
worker, I have the duty to
educate the public on HIV
and PrEP. a
Adolescents and young
adults, including those below
18 years of age, who are at
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3
(16%)

5
(26%)

4
(21%)

-

7
(37%)

1.3
(44%)

-

-

1
(5%)

1.38

2
(11%)

2
(11%)

16
(84%)

2.8
(93%)

-

-

3
(16%)

15
(79%)

2.7
(89%)

0.75

-

-

-

1
(5%)

18
(95%)

2.9
(98%)

0.23

-

1
(5%)

1
(5%)

6
(32%)

11
(58%)

2.4
(81%)

0.84

17
(89%)

2
(11%)

-

-

-

2.9
(96%)

0.32

-

-

2
(11%)

3
(16%)

14
(74%)

2.6
(88%)

0.68

-

-

2
(11%)

1
(5%)

16
(84%)

2.7
(91%)

0.65

16
(84%)

3
(16%)

-

-

-

2.8
(95%)

0.42

15
(79%)

4
(21%)

-

-

-

2.8
(93%)

0.32
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high-risk of HIV infection
should be offered PrEP. a
Counseling should be a part
of any PrEP program. a
Non-clinician staff (nurses,
medical assistants, health
workers) should take an
active role in adolescents
PrEP follow-up and
monitoring. a
Same-Day PrEP should be
made available and offered
to adolescents at-risk for
HIV. a
It is embarrassing to talk
about sex and condom use
with patients, therefore, I
should not initiate to talk
about it with them
Alternative PrEP dosing such
as event-based dosing should
be made available to
adolescents. a
Condoms are for married
people only. Adolescents
should be prohibited from
using condoms.
Parents of adolescents,
particularly those below 18
years of age, who are on
PrEP should always be
involved in their care.
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17
(89%)
17
(89%)

2
(11%)
2
(11%)

-

-

-

2.9
(96%)
2.9
(96%)

0.32

-

-

-

15
(79%)

4
(21%)

-

-

-

2.8
(93%)

0.42

-

-

-

4
(21%)

15
(79%)

2.8
(93%)

0.42

12
(63%)

5
(26%)

1
(5%)

1
(5%)

-

2.5
(82%)

0.84

-

-

-

2
(11%)

17
(89%)

2.9
(96%)

0.32

-

1
(5%)

2
(11%)

6
(32%)

10
(53%)

2.3
(77%)

0.89

0.32

Note: a Positive statements were considered enabling or non-stigmatizing attitudes, the scores for responses
were as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0; Strongly
disagree = 0.
Others were negative statements, reverse scoring were applied to these items when scores allotted.
Attitude item score below 2 is considered stigmatizing attitudes.
SD = Standard Deviation
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Training Workshop Evaluation
Post-training, the participants’ feedback on the online training-workshop and simulation
reveals that providers believed they achieved the objectives set for each module. More than 88%
agreed that they achieved almost all the objectives set for each module at the beginning of the
training.
Figure 3. Post-Training Workshop Evaluation Result on Module 1

As a result of participating in the session
"Module 1: The Basic of STI, HIV and AIDS," I
am able to:
102.00%

100.00%
98.00%
96.00%
94.00%
92.00%
90.00%

Responses

88.00%
86.00%
84.00%
Define and Understand how
Correct
Understand how
differentiate STI,
HIV is
misconceptions HIV affects the
HIV, and AIDS transmitted from
about HIV
body
one person to
transmission
another

Learn how HIV
and AIDS can be
prevented as
well as treated
and managed
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Figure 4. Post-Training Workshop Evaluation Result on Module 2

As a result of participating in the session
"Module 2: Key Elements for Ethical and
Effective HIV Prevention Counseling Practices," I
am able to:
102.00%
100.00%
98.00%
96.00%
94.00%
92.00%
90.00%
88.00%
86.00%
84.00%

Responses

Describe the
Identify the DOs
Describe key
importance of and DONTs of HIV points in PrEP
HIV counseling
prevention
counseling
counseling

Describe what is Describe what is
provider-initiated client-initiated
counseling and counseling and
Testing (PICT)
Testing (CICT)

Figure 5. Post-Training Workshop Evaluation Result on Module 3

As a result of participating in the session
"Module 3: AYA and The SOGI Initiative," I
am better able to:
101.00%
100.00%
99.00%
98.00%
97.00%
96.00%
95.00%
94.00%
93.00%
92.00%

Responses

Describe the
Identify the health
Describe the
Assess, plan, and
characteristics of risks and solutions difference of sex,
intervene for an
adolescents and
for AYA
sexual orientation, AYA client who may
young adults (AYA),
and gender identity. visit to our clinic for
and transgender
primary care
AYA
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Figure 6. Post-Training Workshop Evaluation Result on Module 4

As a result of participating in the session
"Module 4: Pre-Exposure Prophylaxis for
AYA," I am able to:
101.00%
100.00%
99.00%
98.00%
97.00%
96.00%
95.00%
94.00%
93.00%
92.00%

Responses
Describe what Describe PrEP Identify the
Understand
Develop
PrEP is,
effectiveness, barriers of PrEP PrEP resources, confidence to
medication
side effects,
use in
guidelines, and prescribe PrEP
available, and and benefits. adolescents
algorithm. in our practice
its indication.
and young
adults.

Figure 6. Post-Training Workshop Evaluation of the Presenter

Presenter: Igor Mocorro, MPH, RN, PHN.
This speaker's presentation skills were
effective for the content presented.
80.00%
70.00%
60.00%
50.00%
40.00%
Responses

30.00%

20.00%
10.00%
0.00%
Strongly agree

Agree

Neither agree
nor disagree

Disagree

Strongly
disagree
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Participants Plan of Change
Providers were also asked to give at least three changes that they would do in their
practice as a result of participating in the online training workshop (Table 7).
Table 7. Providers’ Plan Change in Practice
Provider
Number
1
1)
2)
2
1)
2)

Change in Practice

Being more comfortable with offering Prep.
Being more open with discussing prep with patients.
I feel more prepared to prescribe PrEP.
I learned more about counseling prior to testing and
will use that when discussing testing.
3) I will open a bigger discussion into sexual activity

3

4

5

6

1) I will approach the young adolescent/adult population
in a more sensitive fashion when doing a health and
social history.
2) I will able to consider some of the barriers to
treatment and knowledge of this age population.
3) I will know how to provide resources to their learning
needs
1) Inquire about sexual history and practice as apart of
primary care visits to Identify health risks
2) Education on importance of safe sex practices
3) Review the use of PrEP for those who are involved in
high risk sexual behaviors

1) Understand and follow the PrEP guidelines. It is easy
for me to understand it since we went over it in this
simulation training date. I also did not know as NPs
we could prescribe PrEP, I thought that only
women’s health NP or other specialists could
prescribe the medication.
2) Be more mindful and aware of my nonverbal
expressions
3) Develop confidence to discuss PrEP and sexual
histories
1) Balance empathy with professionalism, not being
overly reassuring
2) Implement harm reduction tactics versus full

Change Focus
Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
Use of PrEP Guidelines,
Protocols, and Algorithms
Prevention and Counseling
Use of PrEP Guidelines,
Protocols, and Algorithms

Assessment and Risk
Identification,
Prevention Education and
Counseling
Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
Prevention Education and
Counseling

Assessment and Risk
Identification
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3)
7

1)

2)

8

1)
2)
3)

9

4)
5)
1)
2)

3)
10

1)
2)
3)

11

prevention framework regarding high-risk behaviors
Demonstrate confidence and confidentiality while
taking a sexual history to promote trust and disclosure
I will feel more comfortable talking to this age group
about sex. I will be able to initiate difficult
conversations about sex.
I will be able to adequately gather a health history
that includes details about sexual health. I will use the
information I gained about confidentiality for
adolescents and young adults that use their parents'
insurance to ensure that patients get the treatment
they need and are able to maintain confidentiality.
Ask questions to open up dialogue about
STI/HIV/AIDS in addition to safe sex & protection
Reassurance & support about patient options and
choices.
Provide all pertinent info needed on STI/HIV/AIDS
to make educated decision
Be confident in using PEP & PrEP in clinical setting
Report as mandated per CDC
Prepare and have ready handouts related to physical
anatomy and STIs and prevention
Be aware of ways to help AYA access PrEP and PEP
through community resources/LGBTQ support
services
Routinely screen AYA regarding sexual health and
drug use.
Initiate HIV/AIDS/STI discussion without fear
Use CDC guidelines for management of STIs and to
understand required reporting responsibilities
Determine appropriate HIV/AIDS interventions by
using the Primary Care HIV/AIDS algorithm and
proper use of PEP and PrEP

1) STD counseling
2) HIV risk assessments
3) PrEP prescribing and health monitoring.

63
Prevention Education and
Counseling
Assessment and Risk
Identification
Plan of Care and Evaluation

Assessment and Risk
Identification
Prevention Education and
Counseling
Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
Prevention Education and
Counseling
Plan of Care and Evaluation
Assessment and Risk
Identification
Prevention Education and
Counseling
Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
Prevention Education and
Counseling

12

1) Parents involvement not necessary to protect patients
confidentiality for minors
2) Be more open in sex education teaching

Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
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13

14

15

16

17

18

19

3) Identifying their concerns and addressing them
regarding sexuality
1) I don't work with AYA very much but I will certainly
remember this material for when/if I am working with
this population and will apply it to my adult practice.
2) It is so important to always talk about sexual health
with AYA but also with the adult and elderly
populations.
1) Thorough questioning of sexual practices and
preferences
2) Addressing questions and lack of knowledge early
3) Encouraging patient confidence by providing
resources

1) Learn to identify premature or unsafe sexual
expression.
2) Gained confidence in furnishing PrEP to this
population.
3) Learned how to educate this population on PrEP.
1) Assessing the physical, mental, and social
determinants of health for AYA
2) Offering PEP and PrEP, and connecting them with a
PrEP navigator to assist with financial and housing
assistance
3) Encouraging safe sex practices- prevention,
screening, prophylaxis
1) More information gained, therefore, more
information shared
2) Introduce AYA about the availability of PrEP and
PEP in preventing HIV
3) Help prevention of spread of HIV among all
population actually not just AYA.
In primary, I would
1) Advocate for youth health
2) STD screening for LGBT youth
3) Educate about PrEP
1) Asking about sexual encounters.
2) Offer PrEP
3) Offer more PrEP counseling.
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Prevention Education and
Counseling
Prevention and Counseling

Assessment and Risk
Identification
Prevention Education and
Counseling
Plan of Care and Evaluation
Assessment and Risk
Identification
Prevention Education and
Counseling
Assessment and Risk
Identification
Prevention and Counseling
Use of PrEP Guidelines,
Protocols, and Algorithms
Assessment and Risk
Identification
Prevention Education and
Counseling
Assessment and Risk
Identification
Prevention Education and
Counseling
Assessment and Risk
Identification
Prevention Education and
Counseling
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Section V. Discussion
Summary
The purpose of the AYA ComPrEP Project is to standardize PrEP screening tools,
guidelines, and protocols to increase PrEP services provision for adolescents and young adults.
In particular, the project aimed at integrating PrEP into the practice of Balboa Teen Health
Center. However, due to closure of the school and the clinic, the primary outcomes were
limited to conduct of the online training and workshop for the clinicians of the University
of San Francisco. The goals of the online training workshops were achieved. Clinicians of
the University of San Francisco who participated in the online training workshop had
increased knowledge on HIV and PrEP (mean post training knowledge score of 86%). At
least 80% of the clinicians who attended the training workshop have had increased in
enabling or non-stigmatizing attitudes on HIV and PrEP (mean post training attitude
score of 88%). Also, during the simulation, 100% of the providers used the guidelines (e.g.
risk assessment tool and protocol) in case studies provided to them, demonstrating their ability to
decide the plan of care of patients who need PrEP. Likewise, 100% (n=19) of the clinicians
have stated increased comfort in prescribing PrEP to AYA patients after the simulation.
At CHPY, fortunately, the leadership is interested to having this project
implemented and there is an on-going support for the author to train providers and clinic
staff to provide PrEP services and integrate the PrEP protocol at Balboa Teen Health
Center. While PrEP is currently a part of the services offered by CHPY clinics, there is
the need to solidify protocols and procedures and to roll out PrEP services at Balboa Teen
Health Center. Although it is intended that the project will effectively increase PrEP offering
and prescription to patients of Balboa Teen Health Center, there were some setbacks or delays.
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The author at the start anticipated possible challenges related to the implementation of
the project such as push back from some clinic staff, particularly medical assistants who
maybe not interested in doing interventions beyond drawing labs and providing
counseling. This however was not evident for Balboa Teen Health Center based on the
results of the in-depth interviews. Staff were supportive to bring PrEP services in the
clinic although the results of the roll out of the actual PrEP services is yet to be seen. The
shelter-in-place policy for San Francisco due to COVID-19 pandemic has delayed the
actual implementation of the PrEP services at Balboa Teen Health Center. If it will push
through, the author anticipates that the time required to effectively screen AYA for PrEP
services may be seen as a barrier, reducing time from other clinic activities. In that
context, it could be perceived as an added burden impeding clinic flow.
Another challenge that the project may face is the transition to a new electronic
health record for the entire SFDPH. The eCW software is now replaced by EPIC
software. The author planned to be in consultation with the SFDPH IT team, which
manages the software and electronic medical system of SFDPH to ensure that the
screening tools or templates will be fully integrated into EPIC. However, based on the
consultation, this maybe easy said than done. It was suggested though that the template
for risk assessment or screening could be written on a Microsoft Word and then copied
pasted to EHR if a built-in template is not possible to create right away. It is important
that all clinic team members realize the value of the project and that everyone takes
ownership. The continuation and sustainability of the project would be most successful if
it is experienced not as a burden or extra work, but as an integral piece of the services
CHPY provides for key populations most affected by HIV. The community clinics of
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CHPY were developed specifically to mitigate the impact of the epidemics and health
disparities on young people.
Interpretation
This project expected to improve the knowledge, enabling attitudes, and confidence of
providers to provide PrEP services to adolescents and young adults. Results from the in-depth
interviews of Balboa Teen Health center providers and staff show showed a great interest and
enthusiasm to make PrEP services available in the clinic. The results from the interviews
indicated the need for improvement in the clinic workflow and determination of roles and
responsibilities in the roll out of PrEP services for AYA such as improving communication
among staff, understanding the role of the PrEP navigator and staff from the San Francisco
Unified School District (SFUSD) who are part of the Balboa Team Health Center team.
The training workshop, which was modified to implement online and to target USF NP
students, showed the lack of knowledge on PrEP for some providers such as knowledge on
PrEP protection for vaginal sex, protection for people who inject drugs, HIV transmission
by needle stick injury, and the frequency of testing for most-at-risk patients. Likewise,
despite of the training workshop, some providers still showed stigmatizing or nonenabling attitudes on the areas of blood donation from homosexuals, and mandated
disclosure for those who have HIV-positive status to their partners.
Limitations
The AYA ComPrEP had some limitations; some of the interventions were not implemented
or were modified due to the ‘shelter-in-place’ policy in the San Francisco Bay Area related to the
COVID-19 pandemic. The PrEP training workshop for providers and staff of Balboa Teen Clinic
scheduled on March 13, 2020 was canceled due to the school and clinic closure. While it was agreed
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between the author and the clinic management to continue the training intervention for staff of
Balboa Clinic, the date is unknown and it would not happen until the resume of classes at Balboa
High School and the re-opening of the health center. While the training workshop piece was
modified to involve nurse practitioner students of USF through an online training workshop and
simulation, the project only measured the increase in knowledge, enabling attitudes, and

confidence of clinicians post-training.
The participants were asked to identify three changes that they plan to implement
in their practice. This plan may not necessarily lead to actual change in practice.
Providers who completed the online training workshop are unable to immediately offer
PrEP services and depending on the type of their work, not everyone may necessarily be
prescribing PrEP. Since time from the training to the actual provision of PrEP services
may take longer for the participants, their confidence may regress and additional followup PrEP training maybe needed. Despite of the above-mentioned limitations, practice
tools for offering services and prescribing PrEP were provided to the participants so that
providers have resources to use if they need them. Likewise, they were connected to
Lyric (non-profit organization that provides PrEP navigation support and other services
for young people) and the PrEP navigator who expressed his support for continuous
networking and collaboration.
In terms of the training workshop, though the online training workshop for USF
nurse practitioner students was a success based on the feedback on how it was done and
the achievement of the objectives by the participants for each module, doing it online
revealed some limitations such as the time allocated for online simulation. Follow-up
discussions related to the results of the surveys were not done. If follow-up is possible,
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this can create space for continuous discussions, identify emerging issues, and improve
practices. There is a need for more time to discuss further the cases, questions, and
concerns about PrEP for the adolescents and young adults.
While the project measured the increased in knowledge and enabling or non stigmatizing attitudes of the providers who participated in the online training workshop,
no statistical inference can be done between variables. We cannot associate the change in
attitudes with knowledge scores. Likewise, scoring the enabling attitudes brought
challenging ethical issues. While they are based on human rights approaches,
interpretation can varies by situations, state laws. For example, the human rights based
approach uphold confidentiality of HIV test result and a patient who is diagnosed of HIV
should not be forced to disclose their status to their partners, there maybe an ethical
dilemma for some providers on how to deal with such situation. Findings cannot be
generalized to all the nurse practitioner students in the San Francisco Bay Area or in California
in general because neither a random sample was used nor was the sample reflective of the entire
population. However, the results showed interesting findings and support theories that the
conduct of training workshops on any health topics improve knowledge and attitudes. .
Conclusion
The Community Health Program for Youth (CHPY) of the San Francisco Department of
Public Health has the mission to keep adolescents and young adults in San Francisco healthy.
Focusing on PrEP and other protective measures provides an opportunity for San Francisco to
take leadership in HIV prevention. Given the complexity of adolescents and young adults,
without comprehensive interventions, we could slip back into epidemic status. PrEP access by
AYA is possible by breaking the barriers to PrEP prescription through education and training of
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providers and clinic staff. This project demonstrated the needs for providers and clinic staff to go
through PrEP education and training workshop to be able to provide quality PrEP services to
AYA. Nurse practitioner students of the University of San Francisco who participated in the
online training workshop were interested to learn and achieve competency in providing PrEP
services and prescription to AYA. Training on PrEP for AYA (not only for adults) in primary
care setting should be provided to all NP students across the nation. They need more discussions
about issues of blood donations by key populations, HIV disclosure, and prevention of needle
stick injuries. Stigmatizing attitudes should be addressed in PrEP and HIV education and training
clinicians. Evidence-based research such as U=U (undetectable viral load = untransmittable
HIV) should be discussed to eliminate stigmatizing attitudes and promote enabling environment
for our most-at-risk populations. At times of COVID-19 pandemic, online simulation training
workshop on PrEP was an effective alternative means if face-to-face training is not possible.
The American Nurses Association (ANA) provides guidance on HIV and AIDS Nursing
Scope of Practice and also addresses these infections in the more general Standards Scope for
Nurses. Promoting effective HIV prevention with PrEP and empowering adolescents to reduce
the risk of HIV transmission is within the nursing scope of practice, which includes assessing
patient risk, creating plans for adherence, continuity of treatment, and evaluating patient
response. While primary care clinicians, including nurse practitioners, physicians and physician
assistants, play an important role in prescribing PrEP, registered and vocational nurses, health
workers, and medical assistants have the capabilities needed to close the gap between the
prescriber and the patient through PrEP education and counseling, conducting PrEP follow-up,
and adherence support.
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PrEP is a vital component of a robust HIV-prevention program in high-risk communities.
This medication has proven to be safe and effective and is easy to prescribe and monitor.
Currently, it is the only effective pharmaceutical interventions available to prevent HIV
infections in key populations who engage in high-risk behaviors. PrEP can be prescribed by
primary care clinicians, including advanced practice nurses and should be made accessible to
AYA patients at risk of HIV infection, regardless of their socio-economic status or other
background factors. If PrEP becomes widely accessible, including to high-risk adolescents and
young adults, new HIV infections and the burden of lifelong HIV infection will be averted. Key
populations such as young men who have sex with men will live healthier lives free from HIV
and associated illnesses and co-infections.
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Section VIII. Appendices
Appendix A. Types of PrEP Dosing
Types of PrEP Dosing

Daily PrEP

Dosing Description

TDF/FTC taken the same time daily.

Number of tablets per
week
7 tabs

Alternative PrEP dosing
(non-daily PrEP)
On-demand PrEP

Event-Driven PrEP

Time-Driven PrEP

Intermittent PrEP

TDF/FTC before and after sexual
activity: taking a loading dose of two
tablets of TDF-FTC or placebo with food
2 to 24 hours before sex. A third pill
followed this dosage 24 hours after the
first drug intake and a fourth pill 24
hours later (Molina et al, 2015).
Similar to on-demand PrEP; take 1 tablet
before and after sex a total of 2 tablets
and not 4 tablets as compared to the ondemand PrEP (Grant et al, 2018).
Taking 1 tablet of TDF/FTC (Truvada)
twice weekly with a post-sex dose, which
59 participants were given in the study of
Grant et al (2018)
Taking a pill of TDF/FTC on Monday
and Friday, and 1 pill within 2 hours after
sex, not to exceed 1 dose per day (Mutua
et al, 2012).

4 tabs

2 tabs

2 tabs + 1 tab after sex

2 tabs + 1 tab after sex
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Appendix B. Evidence Tables
Table 1. Provider-Associated Barriers in AYA PrEP Use
Question: What are clinician-perceived barriers to AYA PrEP use?
Author

Type of Evidence and

Study Findings

Limitations
Low response rate
and therefore
possible sample bias.

Statistical Tools Utilized
1) Hart-Cooper
et al, 2018

Non-experimental Quantitative
Study

Nearly all providers had heard of PrEP (93.2%) and
a third (35.2%) had prescribed PrEP.

Evidence
Rating: Level
III, Quality B

Cross-sectional online survey

Almost all providers agreed that PrEP prevents HIV
but fewer were willing to prescribe PrEP to young
adults (77.8%) or adolescents (64.8%)

Sample Size:
162 clinicians
Date: Between
October 2016
and January
2017

Descriptive analyses used to
examine independent variables and
outcomes (willingness to prescribe
PrEP):
• Means and SD (continuous
variables)
• Frequencies or Percentages
(categorical and ordinal
variables)
Inferential statistics used using
Stata IC 13.2:
• Univariate and multivariate
binary logistic models – to
predict willingness to prescribe
PrEP

Willingness to prescribe PrEP strongly associated
with belief that:
1) Providers had enough knowledge to safely
provide PrEP to adolescents (OR 2.11, CI:
1.18-3.76, p≤.01 and young adults (OR 5.19,
CI: 2.15-12.50m P.001)
2) Adolescents would be adherent (OR 3, CI:
1.30-6.90, p=0.01)

More respondents
were adolescentmedicine trained;
therefore might be
more willing to
prescribe PrEP
compared to most
adolescents’
providers
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2) Mullins et al,
2017
Evidence
Rating: Level
III, Quality B
Sample Size: 56
clinicians

Non-experimental Quantitative
Study
(Internet-based Survey through
SurveyMonkey)
Descriptive analyses used to
examine independent variables and
outcomes (clinicians’ PrEP
prescription intention and actual
PrEP prescribing)
Statistical analyses:

Date: Between
January and
April 2014

*Sign test for paired data used to
compare intention to prescribe to
adults versus adolescents
*McNemar’s test used to compare
actual prescription of PrEP to
adults versus adolescents
*Univariate and multivariate
logistic regression models were
used to examine independent
variables associated with intention
and actual prescription of PrEP

3) Mullins,
Zimet, Lally,
Kahn, 2016
Evidence
Rating: Level

80
Clinicians had greater intention to prescribe PrEP to
adults compared with adolescents

Small sample size
but high response
rate; findings
Decreasing perceived provider-level barriers and
barriers related to PrEP use in patients younger than provided the basis
18 was associated with improving access to PrEP for for pilot data
adolescents
Recruitment of
participants through
Cost of insurance was associated with decreased
a single research
intention of PrEP prescription to youth
network
More experience in non-occupational post-exposure
No assessment of the
prophylaxis (nPEP) was associated with actual
composition of
prescription of PrEP
clinicians’ practices
Perceiving that multi-disciplinary teams and
concerning patient
behavioral interventions are not necessary for PrEP
risk categories (e.g.
delivery were associated with prescription intention
clinicians may not
and actual PrEP prescription
have had many
homosexual or
bisexual patients)

Non-experimental

Clinicians’ perception of patient-level barriers:

Qualitative Mixed-methods Study

1) General lack of awareness of PrEP among AYA
patients, especially those who might benefit from
taking it

(Face-to-face and semi-structured
phone interviews, open-ended
questions)

2) Lack of clarity among AYA on policies about
PrEP, parental permission, and confidentiality;

Participating
clinicians may not
have had actual PrEP
prescribing
experience
Recruitment of
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III, Quality B
Sample Size: 15
clinicians
Date: Between
October 2, 2012
and April 23,
2012

Descriptive analyses
Data analyses using five-step
framework analysis approach
(familiarization, identification of
thematic frameworks, indexing,
charting, mapping, or
interpretation) and employing
NVivo (version 10)

81
patients were unaware that PrEP is classified as
protected confidential care for adolescents
Provider-level barriers include:
1) Concerns about PrEP adherence by patients, and
PrEP monitoring visits, including viral resistance
development due to incomplete adherence
2) Concerns about risk compensation; for example,
the concern that patients might participate in riskier
behaviors such as unprotected sex because they felt
protected from HIV infection

Data analyses of barriers
categorized in four levels: patients,
providers, organizations or systems,
Concerns of prescribing to youth under 18:
and community-level.
1) Maintaining confidentiality

2) PrEP as a controversial therapy and possible
negative publicity when prescribing PrEP in a
pediatric practice
3) Side effects and toxicity (e.g. negative effects of
PrEP on bone density, accrual in cells and tissues,
and renal function)
Organizational and system-level barriers:
1) High cost of PrEP, inadequate or lack of medical
insurance
2) Negative attitudes of colleagues
3) Systems limitations
4) Lack of resources including clinic space,
providers’ time, and adequate support staff
5) Access in the community: for example,

clinicians through a
single research
network
Sample size
relatively small
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unwillingness to fill PrEP prescriptions by pharmacy
staff
6) Lack of awareness of PrEP among primary care
providers
Community-level barriers identified include stigma
on HIV infection and sexual minorities

4) Mullins,
Lally, Zimet,
Kahn, 2015
Evidence
Rating: Level
III, Quality B
Sample Size: 15
clinicians
Date: Between
October 2, 2012
and April 23,
2012

Non-experimental
Qualitative Study
(Qualitative Interview followed by
a Survey)
Data analyses using five-step
framework analysis approach
(familiarization, identification of
thematic frameworks, indexing,
charting, mapping or interpretation)
and employing NVivo (version 10)

Clinicians were somewhat or very familiar with the
guidance on prescribing PrEP in heterosexual adults
(9/15), and adult MSM (13/15)
Clinicians described characteristics of people who
would and would not be appropriate for PrEP,
including:
1) presence of mental health illnesses or diagnoses,
and/or 2) substance abuse issues. These are
indicators of a person engaging in higher risk sexual
behavior, with issues that could also negatively
impact adherence to PrEP.
Use of PrEP thought to be appropriate for
serodiscordant couples attempting pregnancy
There were concerns about the period of potential
infection during PrEP initiation
Most clinicians reported that behavioral
interventions such as counseling on sexual practices
should be a necessary part of PrEP interventions.

Recruitment of
participants through
a single research
network but
practicing in
different clinical
sites
Limitation of results:
Understanding of
clinician attitudes,
intentions, and
practices were based
on small sample
size.

Study sample
included those with
experience
Suggestions for PrEP delivery included: 1) condom
prescribing PrEP.
use and safer sexual behaviors; 2) education on PrEP
Clinicians who had
risks and benefit, adherence to PrEP, 3) substance
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use avoidance, and 4) building or developing selfesteem

not prescribed PrEP
were not part of the
study.
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Table 2. Patient-Associated Barriers in AYA PrEP Use
Question: What are AYA perceived barriers to PrEP use?
Author

Type of Evidence and

Study Findings

Limitations

Statistical Tools Utilized
5) PerezFigueroa,
Farzana, Staci,
Eddy, and Perry,
2015
Evidence
Rating: Level II,
Quality A
Sample Size:
100 included in
the analyses, of
200 HIVnegative YMSM,
biologically male
invited
Date: Between
October 2, 2012
and April 23,

Non-experimental

Three primary concepts:

Qualitative Interview followed by a
Survey
A semi-structured interview,
included open-ended questions

1)
•
•
•

Participants recruited from the P18
study (parent study)

•

Data interviews transcribed, coded,
and analyzed using NVivo 10
(Welsh, 2002)

Awareness of PrEP:
50% were aware of PrEP
Some compared PrEP to birth control.
Despite awareness, participants (i.e. potential
patients) expressed hesitation about PrEP use.
The majority expressed a desire for more
information about PrEP. Questions include side
effects, types of medications, active ingredients,
odds of contracting HIV, and whether
medication causes HIV.

2) Attitudes toward PrEP
•
•
•
•

PrEP is one of several strategies. another source
of protection other than condoms
Condoms would be easier to remember than
taking daily medication
Consistent condom use equally effective, if not
more effective, than PrEP.
Adherence could be difficult in the long term.
Concern about missing pills and getting HIV,
developing immunity to PrEP, and side effects.

Not all the YMSM
in the sample were at
high risk for HIV.
At the time of the
interview,
participants were
enrolled in the parent
cohort study for two
years; these young
men may have a
better understanding
of HIV prevention,
affecting their views
towards PrEP.
Potential for
(skewed) socially
desirable responses
because the
assessment was
administered by
interviewers
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•

2012

Cost of PrEP often voiced by YMSM of color.

3) Social behavioral influences:
•
•
•
•

•

PrEP would provide a means of avoiding
successful condom negotiation
Use of PrEP could justify not using condoms
The desire to engage in sex without a condom as
a motivator for the adoption of PrEP.
The stigma of PrEP: a prevention strategy for
those who engage in high-risk sexual behaviors
or more frequent casual encounters
Relationship status: PrEP being seen as a trust
and fidelity issue, taking PrEP could mean likely
to have sex outside the main relationship.

PrEP is protective if the partner is having sex
outside of the relationship.
6) Fisher, Fried,
Desmond,
Macapagal,
Mustanski
(2017)

Non-experimental

Evidence
Rating: Level
III, Quality A

Chi-square and multivariate
analyses of variance were
performed to compare responses
across gender identity and age

Sample Size:
150 sample size,

Qualitative surveys
Descriptive analyses using
frequencies, means, SD, and
proportions were used for all survey
responses.

Assessed the relationship between
likelihood of PrEP adherence with

•
•

•

Half of the respondents said they would
participate in a PrEP adherence study
Likelihood of PrEP adherence study
participation significantly increased with the
number of sexual partners, prior HIV or STI
testing, prescription of HRT, the comfort of
youth asking their MD about HIV prevention.
Interest in participation significantly decreased
when the risk of HIV lessened.

Regardless of age and gender identity:
•

About half of the participants were extremely or
somewhat worried about the negative side

The study was
conducted
anonymously, which
may have affected
the certainty of the
inclusion criteria
Sample
predominantly nonHispanic white
The study may not
have included youth
from family-
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from a national
online survey of
transgender
youth; 90 TM
and 60 TF, 45%
under age 18

demographics, family disclosure
and acceptance, and attitudes
toward health benefits and risks of
experimental procedures
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•
•

Multivariate regression used to
examine independent effects

effects of PrEP
One-third of participants did not want to
additional medication to their health regime
One-third were concerned about getting to
quarterly appointments

abandoned,
impoverished, or
homeless situations
who may engage in
sex work or other
high-risk sexual
behavior

Date: Spring
2016
7) Hosek et al.
(2017)
Evidence
Rating: Level
III, Quality B
Sample Size: 78
participants were
included in the
analyses among
260 eligible
Date: Between
August 2013 and
September 2014

Quasi-experimental
Participants were recruited through
the clinical sites affiliated with
ATN in person and online
Demographic and risk
characteristics of the study
population were examined using
descriptive analyses
All analyses conducted using SAS,
version 9.4.
Fisher Exact Test used to examine
bivariable relationships between
study outcomes and categorical
characteristics
Wilcoxon rank sum test used to
examine bivariable relationships
between study outcomes and
continuous characteristics

The first study on the safety and implementation of
PrEP among adolescents MSM
•

•

•

•

•

Generalizability of
the findings maybe
limited due to small
Detectable TFV-DP drugs level in most
participants throughout the study, 95% in first 12 sample size and lack
of participation from
weeks but declining levels of drugs thereafter
No statistically significant associations between some ATN sites
Pharyngeal swab
sex without condom use or receptive anal
intercourse without condom use with last partner testing and samples
were not collected.
and TFV-DP levels over time
Urine and rectal
In comparison with respondents with protective
swabs were only
levels of TFV-DP, those without protective
levels were more likely to endorse the statement, obtained at 24 and
“I worry others will see me taking pills and think 48 weeks. May have
underestimated rates
I am HIV-positive.”
Most common reasons for missing doses of PrEP of STIs in the
sample
were: 1) being away from home; 2) being too
busy; 3) forgetting; 4) changes in routine
There was a decreased in acceptability of pill
size and taste from 12 weeks to 48 weeks among

Time and resources
needed to conduct
this study were
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McNemar test used when
comparing binary measures
between time points among
participants
8) Koss et al.
(2018)
Evidence
Rating: Level
III, Quality A
Sample Size:
254 to 993
samples
depending on
criteria used

Non-Experimental
Demographic and risk
characteristics of the study
population were examined using
descriptive analyses
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study population

Adherence to PrEP waned over time among youth,
particularly after week 12.
Self-report of YMSM about using PrEP
overestimates their actual adherence

Spearman correlation used to assess
between pharmacologic (hair and
DBS) and non-pharmacologic (selfreport and Wisepill) measures

Evidence

Wisepill devices
were to provided to
all study participants
Reasons for Wisepill
non-openings (e.g.,
pocketed doses)
were not collected
Participating YMSM
were not asked their
likelihood to use
Wisepill in the future
Recall of pill-taking
over preceding 30
days were measured
based on self-report

Date: Between
August 2013 and
September 2014
9) Holloway et
al., 2017

substantial, may
limit the ability to
replicate findings in
future clinical trials

Anonymous survey data analysis

Willingness to take PrEP was significantly
associated with:

Demographic and risk
characteristics of the study

1) Time since last HIV test
2) Level of concern about becoming infected with

Convenience
sampling and the use
of willingness as a
primary outcome
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Rating: Level
III, Quality B
Sample Size:
762 participants
included in the
analyses
18-29 assigned
male at birth,
sexually active
with other men
in the last five
years., HIV
negative, and
California
residents
Date: Survey
data collected
online from July
9 to August 20,
2015
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population were examined using
descriptive analyses

HIV

Multivariate regression

4) Use of illicit drugs in the past six months

measure

3) Recent receptive condomless anal sex
5) HIV risk index score
YMSM unwilling to take PrEP had more concerns
about stigma, drug effects, risk compensation,
necessity, medical mistrust, adherence, and
access/affordability.
Hispanic/Latino patients more likely than white to
take PrEP
YMSM with medium and high concern for getting
HIV were nearly twice as likely to be willing to take
PrEP compared to YMSM reporting a low concern

Participants were a
self-selected group,
may represent a bias
towards those who
are more interested
in PrEP
Self-reported data
may mean over or
under reporting of
willingness to take
PrEP

Increased medical mistrust associated with
decreased willingness to take PrEP
Greater concern about adherence associated with
lower willingness of PrEP intake. Higher scores on
perceived benefits associated with higher likelihood
of desire to take PrEP.

The study may have
missed essential
issues for YMSM
that influence
willingness to take
PrEp

Running head: PROJECT OVERVIEW PAPER

89

Appendix C. Statement of Non-Research Determination Form
DNP Statement of Non-Research Determination Form
Student Name: IGOR G. MOCORRO, MPH, BSN, RN, PHN

Title of Project: Adolescents and Young Adults Comprehensive PrEP Education Project
(AYA ComPrEP)
Brief Description of Project:
A) Aim Statement:
Goal: To improve HIV prevention in adolescents and young adults (AYA) by
preparing clinicians and/or clinic staff to confidently provide PrEP services to this
population
Aim: By April 2020, clinicians who participated in the training workshops will
demonstrate increased knowledge and comfort to provide HIV prevention education
services via a post training evaluation, and at least 80% will be ready to prescribe
PrEP to at-risk AYA as demonstrated by actual prescriptions.
B) Description of Intervention:
Interventions of the AYA ComPrEP will include the creation of a
comprehensive PrEP educational program with emphasis on PrEP and condom use
initiation and prescription and condom use. An analysis of what constitutes an
effective HIV and STI prevention program acceptable to AYA in the San Francisco
Bay Area has been done in the previous year. The project interventions be divided in
four major phases:
•

Screening Tools Development

1.1 Develop by January 2020 the risk assessment and screening tool for clinical staff to
improve identification of AYA patients at substantial risk for HIV and increase
provider offer of PrEP at CHPY clinics. This can be done by revising the existing STI
screening tools of CHPY to include screening on risk of HIV infection based on available
risk assessments such as the Clinical Practice Guideline of the CDC, and the PrEP Education
for Youth-Serving Primary Care Providers Toolkit developed by the Sexuality Information
and Education Council of the United States (SIECUS).
1.2 Develop a model algorithm and screening protocol for implementing PrEP by January
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2020 by looking at policy in nursing algorithm, evidence-based practice and the
recommendations of PrEP experts, clinicians, and staff.
1.3 Produce the AYA ComPrEP kits. These are bags that contain freebies and educational
materials on PrEP and HIV prevention similar to the Quit Smoking Kit being distributed by
the San Francisco Department of Public Health.
•

CHPY Staff and Providers Trainings and Seminars.

2.1 Conduct the AYA ComPrEP training seminar for CHPY clinicians and staff by
March 2020.
2.2 Implement the risk assessment and screening tool in at least 2 CHPY clinics by
April 2020.
2.3 Create an online platform on PrEP, HIV and STI prevention that is accessible and
user friendly for AYA patients March 2020.
•

Screening Tools and PrEP Protocol Implementation

3.1 Implement the model algorithm (use of risk assessment and screening tool) in at
least one CHPY clinic for 6-8 weeks by April 2020
•

Project Evaluation

4.1 Evaluate the clinical staff and providers’ comprehension and comfort to initiate and
prescribe PrEP
4.2 Evaluate the ‘AY ComPrEP’ by April/May 2020.
C) How will this intervention change practice?
This intervention will change practice by standardizing practice in CHPY clinics to improve
clinicians and staff PrEP initiation and prescription to most-at-risk AYA patients,
increase awareness and access of AYA patients to PrEP, and maintain 0% HIV
infection rate among AYA patients on PrEP and condom use.
D) Outcome measurements:
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Post-training evaluation for clinicians and staff by April 2020:
• At least 80% of the clinicians have increased knowledge and comfort to
prescribe PrEP to its AYA patients
• At least 80% of the clinicians who attended the training workshop have will
have:
o Increased knowledge on HIV and PrEP
o Increased in enabling or non-stigmatizing attitudes on HIV and PrEP
o Used the guidelines (e.g. risk assessment tool and protocol) in
practice or demonstrated in the case studies simulation; and
o Stated increased comfort in prescribing PrEP to AYA patients after
the implementation/simulation.
Post-AYA ComPrEP evaluation by April 2020:
• 100% of the providers or staff were using the risk assessment in every patient
screening over the 6-8 weeks period. Clinicians were able to decide how to measure
risk.
•

80% of the providers are satisfied with the implementation of the risk assessment and
implementation of PrEP protocol (Feasibility of the risk assessment algorithm)

To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used:
(http://answers.hhs.gov/ohrp/categories/1569)
☐ This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). Student may proceed with implementation.
☐This project involves research with human subjects and must be submitted for IRB approval
before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *
Instructions: Answer YES or NO to each of the following statements:
Project Title:
The aim of the project is to improve the process or delivery of care with
established/accepted standards, or to implement evidence-based change. There is no
intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is a
part of usual care. ALL participants will receive standard of care.
The project is NOT designed to follow a research design, e.g., hypothesis testing or
group comparison, randomization, control groups, prospective comparison groups,

YES
✓
✓
✓

NO
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cross-sectional, case control). The project does NOT follow a protocol that overrides
clinical decision-making.
The project involves implementation of established and tested quality standards
and/or systematic monitoring, assessment or evaluation of the organization to ensure
that existing quality standards are being met. The project does NOT develop
paradigms or untested methods or new untested standards.
The project involves implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.
The project is conducted by staff where the project will take place and involves staff
who are working at an agency that has an agreement with USF SONHP.
The project has NO funding from federal agencies or research-focused organizations
and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal research
project that is dependent upon the voluntary participation of colleagues, students
and/ or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following
statement in your methods section: “This project was undertaken as an Evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”
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✓

✓
✓
✓
✓

✓

ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
Evidence-based activity that does NOT meet the definition of research.
IRB review is not required. Keep a copy of this checklist in your files. If the answer to ANY
of these questions is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.
STUDENT NAME (Please print):
_IGOR. MOCORRO, MPH, PHN, BSN, RN__________________________________
Signature of Student:
______________________________________________________DATE__02/15/2019_

SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):
__PRABJOT SANDHU, DNP, FNP-C, PA-C, CNL____________________________
Signature of Supervising Faculty Member (Chair):
______________________________________________________DATE____________
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Appendix D. List of CHPY Clinics and Health Centers
Community Clinics

Location

Services Offered Other
Than Family Planning

1) Cole Street Clinic

Haight-Ashbury District

Primary, Urgent Care

Tenderloin

Primary, Urgent Care

3) Dimensions Clinic

Castro-Mission

Primary Care

4) Hawkins Clinic

Sunnydale

5) ACAC HIV Specialty Clinic

Tenderloin

6) Third Street Clinic

3rd Street

7) Special Program for Youth

Juvenile Justice Center

Primary, Acute

8) New Generation Health Center

Potrero Avenue

Primary Care

*Currently offering PrEP
2) Larkin Clinic
*Currently offering PrEP

Primary Care

Women’s Health
School-based Clinics
9) Balboa Teen Center

Balboa High School

10) Burton Teen Clinic

Burton High School

11) Willie Brown Middle School

Willie Brown Middle

Health Center

School

Primary Care
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Appendix F. Project Information for In-Depth Interview Participant
Doctor of Nursing Practice – Family Nurse Practitioner
School of Nursing and Health Profession | University of San Francisco
In partnership with the Community Health Program for Youth
San Francisco Department of Public Health
Adolescent and Young Adult Comprehensive PrEP Education Project (AYA ComPrEP)
By: Igor Mocorro, MPH, BSN, RN, PHN | USF DNP-FNP Cohort 2020

PROJECT INFORMATION
A. Purpose and Nature of the Assessment
Under the supervision of Jodie Sandhu, DNP, FNP-BC, PA-C, and Stefan Rowniak, PhD,
FNP-BC, Professors of the Doctor in Nursing Program of the University of San Francisco, and
in partnership with the Community Health Program for Youth (CHPY) of the San Francisco
Department of Public Health through its leadership Lori Kohler, MD, Carol Taniguchi, MSN,
PNP-BC, and CHPY PrEP Champion/Coordinator Adam Leonard, MSN, PNP-BC, I, Igor
Mocorro, MPH, RN, PHN, a student of the DNP-FNP of USF is conducting a needs assessment
on the barriers and opportunities to support the creation of a school-based PrEP Program for
adolescents in San Francisco, particularly at Balboa Teen Clinic.
Ultimately, the main aim of this project is to increase our understanding of the needs of the clinic
to support a successful school-based PrEP program to prevent HIV infections among
adolescents/teens or students of Balboa High School and the clinic’s patients. The Community
Health Program for Youth (CHPY) intends to use the information as a foundation for future
endeavor in programmatic interventions on PrEP for adolescents. They will use data collected to
design a PrEP educational program that will address the PrEP needs of AYA. There are a
number of organizations campaigning for PrEP for adolescents and young adults; however
barriers to PrEP in school-based setting in particular have not been a primary focus.
You have been invited to participate because you are a member of the staff of a CHPY clinic
who has expertise and knowledge about the current condition of the clinic for which you work.
Also, you have connections with the patients whom we believe will benefit from the needs
assessment and the AYA ComPrEP Project.
B. Procedures and Processes Involved in Participating
I would like to make it clear that your participation in this project is entirely voluntary. It is your
choice whether to participate in it or not. If you choose to participate, you are also free not to
answer any of the questions, and you can also decide to stop participating in the one-on-one
interview at any time if you wish. However, we would greatly appreciate you letting us know the
reason for not answering any question, or for withdrawing your participation, so that we can
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improve our project methods.
In terms of the process, if you choose to participate in this study, I will set up an interview. I will
be recording the interview discussion with your permission. The interview will include questions
about barriers and opportunities to PrEP implementation in your clinic such as ones about
existing protocols and algorithms. The interview will take no more than one hour and half.
By May 10, 2019, the report of my findings from this assessment will be complete. If you are
interested, I am glad to send you the output of the project. You can also coordinate with the
leadership of the Community Health Program for Youth for information on any future studies,
projects, or programs that may come out of this assessment.
C. Confidentiality and Potential Risks of Participating in the Study
This project is taking every possible step to ensure confidentiality of any and all personal
information on participants. I know that breaches of confidentiality could lead to problems for
participants, so I have taken the following measures to avoid this from happening. 1) I do not
write the name of the participant or his/her place of work (i.e. the in-depth who is providing us
with information about his/her PrEP experiences in the clinic) on any paper that would allow
someone to link the gathered information to him/her. 2) Names of participants and other
identifying information will not appear in any published reports or presentations about this
assessment. All forms used in this project will be stored in a locked cabinet or cupboard to which
only the project team/committee has access. These data will be destroyed as soon as they are no
longer needed.
D. Discomfort that you might experience as a participant
The interview includes questions that may make you feel uncomfortable at times, and it may
bring up topics that are difficult to talk about. It is not my intention to make you uncomfortable. I
want you to know that you do not have to answer any question or take part in the interview at all
if you feel the questions are overly personal or if talking about the topic makes you
uncomfortable.
E. Potential Benefits for you and the community in relation to your Participation
There will be no direct benefit to you for participating in this study. However, I hope that your
involvement will be interesting for you, as it might shed some light on some issues/concerns you
may have, and also on rewards that you experience in working at this clinic. I also hope that you
will learn from the interview process and from any discussions, which may arise as a result of
doing it. Through these interviews with the staff members of the clinic, we hope to be able to
gather rich and valuable information that will assist CHPY and other local and national efforts to
understand the needs of adolescents and young adults in school-based setting to access PrEP
services and HIV education for the prevention of HIV.
F. Cost and Compensation
There will be no cost for you to participate in this research. If you decide to participate in the
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study, I will provide you with a gift card as an appreciation of your time and effort.
G. Alternatives
You are free to choose not to participate in this project without any effect on your future status
with USF and CHPY.
H. Questions
You have spoken to me Igor Mocorro, a DNP-FNP student of USF. I would like to make sure
that you are voluntarily willing to participate in this quality improvement project assessment and
that you have obtained all the information that you need in order to make an informed choice
about your participation. If this information sheet contains words that you do not understand
please ask me and I will take time to explain. You do not have to decide today whether or not
you will participate in the interview. Before you make a decision, you can talk to anyone you
would like to about doing this interview.
If you have any further questions about this assessment that I cannot answer or you have
comments or complaints about the interview, you may contact my professors Jodie Sandhu at
pksandhu@usfca.edu, and Stefan Rowniak at srrowniak@usfca.edu.
CONSENT
You have been given a copy of the information sheet and participation form to keep.
PARTICIPATION IN THIS QI PROJECT ASSESSMENT IS VOLUNTARY. You are
free to decline to participate in assessment, or to withdraw your participation at any point,
without penalty. Your decision about whether or not to participate in this process will have
no influence on your present or future status at the University of San Francisco, and the
Community Health Program for the Youth.
I have read and understand the information on the information sheet, or it has been read to me. I
have had the opportunity to ask questions related to this assessment, and any questions I have
asked have been answered to my satisfaction. I voluntarily participate in this project and
understand that I have the right to end the interview at any time.
Signature/initial of participant: ________________________________
Signature/initials of interviewer: ________________________________
Date of interview: _________________________________
Date of interview: _________________________________
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Appendix G. In-Depth Interview Questionnaire
Doctor of Nursing Practice – Family Nurse Practitioner
School of Nursing and Health Profession | University of San Francisco
In partnership with the Community Health Program for Youth
San Francisco Department of Public Health
Adolescent and Young Adult Comprehensive PrEP Education Project (AYA ComPrEP)
By: Igor Mocorro, MPH, BSN, RN, PHN | USF DNP-FNP Cohort 2020
CODE: __________________________________________________
Place/location: ___________________________________________
Date and Time: ___________________________________________
Survey Questionnaire Facilitator: _____________________________

Assessment Tool:
In-Depth Interview for CHPY Staff
Introduction
Good morning/afternoon. I would like to thank you for taking the time to meet with me and to
share your opinions and expertise on this subject. My name is Igor Mocorro. I am a graduate
student in the Doctor of Nursing Practice – Family Nurse Practitioner at the University of San
Francisco. I am working with the Community Health Program for the Youth (CHPY) on this
project.
I believe that you have received the information of this project ahead of time/before this meeting.
If you have any questions, we can talk about them while we go through the Study Information
and Participation forms. I will need to get your agreement before I start the interview and make
sure that all of your questions and concerns are addressed.

Briefly discuss with the interviewee the Study Research Information/Participation Forms and
obtain their agreement to proceed with the interview.
I understand that you may need to take a break from the interview. Please don't hesitate to let me
know if you need that. Do you have any questions before I start?
I also just wanted to let you know that I look at PrEP as a pill to take daily; an effective
preventive tool for HIV infection for people who are at risk of HIV infection. Currently,
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) also known as Truvada™ is the
only pharmaceutical interventions in oral form that shown in clinical trials to prevent HIV
transmission that has approval by the FDA, including to adolescents. Do you have any questions
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before we start?

Questions:
I. Introduction
1. How long have you been working in this clinic or with CHPY?
2. How would you describe your overall experience working at CHPY?
3. Please describe how you feel about the care being provided at this clinic or at CHPY in
general.
4. How do you feel about the PrEP services, resources and programs offered at CHPY?
II. General Attitude about HIV and PrEP
1. What do you think of HIV and AIDS?
2. In what way do you think HIV and AIDS affects the lives of adolescents and young
adults?
3. What do you think about PrEP?
4. What are your views about adolescents taking PrEP?
5. To what extent do you feel comfortable discussing sexuality, sexual health, HIV, and
HIV prevention services such as PrEP with your clients or patients? Why? Why not?
6. To what extent do you feel comfortable discussing HIV and PrEP in a school-based
setting?
III. Experiences of PrEP
1. How do staff or clinicians here approach patient’s HIV risk?
a. Please explain how important is it for you to screen every patient on HIV risk.
2. With regard to PrEP services, do you think adolescents are treated differently?
a. And if so how?
3. What do you appreciate about the current HIV prevention services offered at CHPY?
a. What, if any, policies/regulations/practices regarding HIV prevention and PrEP at
CHPY seem to work well?
4. What challenges/problems if any have you found in providing HIV prevention services at
CHPY? How about with PrEP?
IV. Programs and Services
1. If you identify a client who is at risk for HIV infection in this clinic, what do you usually
do? What opportunities would you have to help the client reduce his/her risk?
a. What sort of support from colleagues is available for you?

PROJECT OVERVIEW PAPER

101

b. What might the barriers be in developing a PrEP Program in this clinic?
2. What information or educational programs have been provided to clients or patients in
this clinic about HIV and AIDS? How about PrEP?
a. Have you participated in any of these programs? Why or why not?
b. Has the clinic informed clients about their risk?
3. How available are safer sex supplies such as condoms and lubrication here in this clinic?
4. What type of prevention materials such as pamphlets, flyers, posters, videos, or websites
do you think you are allowed to provide to clients in this clinic?
a. Would you feel comfortable having or using such things here in this clinic?
5. Would you know what to say to a client who experiences side effects from taking PrEP?
6. Would you know what to do if a client decided to stop his/her PrEP intake?
V. Moving Forward/ Conclusion
1. What general changes could be implemented in the facility to better support your knowledge
and skills of HIV prevention, particularly on PrEP?
1. What could the CHPY management or leadership do to better support your PrEP services
in this clinic?
2. What facility policies could be implemented to better support PrEP for adolescents in this
clinic?
Closing
< Summary of interview outcomes >.
In the next few weeks, we will be analyzing the data from this and the other interviews we are
conducting with other staff. Would it be alright for me to contact you if I have further questions?
Likewise, if you are interested in getting a recording of this interview, we can send it to you. As
an appreciation of your time and efforts participating in this study, I have some
educational/informational materials for you (or other incentives, etc.).
I will be designing a program plan and implement by Spring 2020. The product of this
assessment and project will be presented to USF by May 2020 and to CHPY as well. If you are
interested in learning about the outcome of this assessment and the project, please let me know.
Thank you again for your participation in this project. The information you provided will be very
useful as we move forward with PrEP implementation at Balboa Teen Clinic. If you need to
contact me, please feel free to do so at any time. I wish you good health and a happy life.
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Appendix H. Results of In-Depth Interviews
Demographics
and Introduction

n= 9 staff participated in the in-depth interviews, all works at Balboa Teen
Health Center
6 participants were CHPY staff
3 participants were SFUSD staff

Attitudes about
HIV and PrEP

• All participants wanted to have PrEP services available at Balboa Teen
Health Center.
• Everyone was excited about the project. Everyone believed that bringing
PrEP to Balboa will increase awareness
“In high school, you want young people to have that sense of self care and
be proactive about their health.”
“I am concerned about students, we show them the AIDS quilt but young
people do not understand…. Risky behaviors start to increase because some
students, their education have gaps of this HIV information.”
“We have a parent who called us asking about why we provide birth control
to her daughter. It was hard. It could be the same problem with PrEP .”
‘The thought that this will be the first school-based PrEP in California, one
of the firsts in the United States and countries in the world, excites me.”

Experiences
about PrEP

• 2 out of 9 clinic staff and team members attended a training on PrEP
previously
• Others learned about PrEP through TV ads, word of mouth, meetings

PrEP Program &
Services at
Balboa Clinic

• Each team member has a role to take in this initiative. There is a need to
clarify or communicate roles.
• There is a disconnect between PrEP navigator & clinic staff
• HIV screening & confidentiality –Staff were aware of their roles in
screening, education, counseling, monitoring/follow-up
• Clinic members voiced out the need for materials on PrEP, including
presentation materials about PrEP for AYA for teachers, staff, students, and
patients.
“We [CHPY & SFUSD] have a great partnership. I am glad that DPH is
here.”
“I feel I am in the outside but I am willing to learn and be a part of this
initiative.”
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• Staff members needed education, training, and workshop both for first
timer and as a refresher for those who had a PrEP training previously
before seeing patients in the clinic for PrEP outreach, education/counseling
and PrEP prescription;
• The clinic need good outreach and dissemination strategies to reach
communities and potential patients of PrEP services in Balboa
“We had resistant from some people. If somebody tested positive, what do we
do with that? At what point can we educate the student enough to have safe
communication to bring parents to the conversation.”
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Appendix I. AYA ComPrEP Project Gantt Chart
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2020
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May
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%
COMPLETE

PROJECT DEVELOPMENT
Evidence Research
Baseline Assessment
Statement of Determination
Consultation with CHPY Leaderships

X X

INTERVENTION DEVELOPMENT & PLANNING
Consultations with PrEP Experts
In-Depth Interviews
Creation of Screening Tools
Creation of AYA ComPrEP kits/binders
Creation of PrEP training and workshop modules

X X X

X X X

INTERVENTION IMPLEMENTATION
Education and Training of Staff
Evaluation of training and education
Implementation of screening tools
EVALUATION IMPLEMENTATION
AYA ComPrEP Evaluation
Dissemination of project results and outcomes

100%
X X
80%
May 2020

July 2020

X X X
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Appendix J. Work Breakdown Structure
1.0 Design
1.1 Develop Project Scope
1.2 Needs Assessment/Gap Analysis
1.3 Develop Objectives
1.4 Identify Key Stakeholders
1.5 Develop Project Charter
1.6 Submit Project Charter
2.0 Plan
2.1 Identify Project Team
2.2 Discussion of Roles
2.3 Develop Project Plan
2.4 Develop WBS
2.5 Develop Surveys
2.6 Prepare Staff Training Protocol
3.0 Intervention
3.1 Feasibility Analysis
3.1.1 Site Survey
3.1.2 Review/Observation of Clinic Workflow
3.1.3 In-depth interviews
3.2 Review and Develop Screening Tools, Protocols, and Algorithms
3.3 PrEP Training Workshop
3.3.1 Module 1
3.3.2 Module 2
3.3.3 Module 3
3.3.4 Module 4
3.4 Identify Funding Sources
4.0 Results 4.1 Present Results of Assessment to CHPY and Balboa Teen Health Center Staff
4.1.1 Analyze Survey Findings
4.1.2 Summarize Findings
5.0 Evaluation
5.1 Identify Results of Knowledge, Attitudes, and Confidence to Prescribe PrEP
5.2 Review Training Feedback
5.3 Write Final Report
5.4 Dissemination
5.4.1 DNP Paper
5.4.2 DNP Presentation
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Appendix K. Communication Matrix
Stakeholder
Lori Kohler, MD
Carol Taniguchi, NP
DNP Chairs: Dr. Prabjot
Sandhu
DNP committee: Dr.
Stefan Rowniak

Project Role
Authorization

Item/Event

Special Instructions

Change in practice

Review and approve project

approval

and screening tool intervention

Authorization,
guidance, critique and
assessment of

Assist and support with
DNP project approval

implementation and

development and approval of
DNP project.

evaluation.

DNP Committee

Supervision and

Adam Leonard, NP

guidance of project

DNP author/Project

Project developer,

manager: Igor Mocorro

manager, and evaluator

Change in practice: HIV

Provide supervision,

risk screening protocol

assistance, and support for
development of project.

Change in practice: HIV
risk screening protocol

Develop, implement, and
evaluate HIV risk screening
protocol to optimize PrEP
implementation.
Assist with use of EHR system

EHR system consultant,
clinical data specialist, and
USF health informatics

EHR system navigation

student intern

Baseline clinical data

to conduct baseline clinical

assessment, electronic

data assessment, and with

screening tool

integration of the screening
tool into the EHR.
Provide input for designing

PrEP case manager

Intervention design

Change in practice

appropriate HIV-risk screening
protocol.

Gilead Sciences assistant
director of medical

Provide input for designing

sciences for the West Coast Intervention design

Change in practice

region, and local

appropriate HIV-risk screening
protocol.

representative
San Francisco City Clinic

Intervention design

Change in practice

Provide input for designing
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and SFDPH CHPY

appropriate HIV risk screening

managers

protocol.
Provide input for designing
Intervention design,

City Wide PrEP NP

clinical staff education,
and potential

appropriate HIV risk screening
Change in practice

dissemination

protocol, assist with clinical
staff education, and potentially
disseminate protocol to other
primary care clinics in SF.
Learn and follow HIV-risk

Clinic providers and staff
(MD, NPs, RNs, MAs,
clinic operations manager,
director of nursing)

screening protocol to increase
Intervention recipients

Change in practice

identification of patients at risk
for acquiring HIV and increase
provider offer of PrEP.
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Appendix L. SWOT

Strengths
•

Compassionate and culturally
sensitive environment
Small organizational size
FPACT reimbursement
Patient population represents at-risk
population eligible for PrEP
Chief medical officer and lead
provider support

•
•
•
•

Weaknesses
•
•
•

Opportunities
•
•
•
•
•

At-risk patient population
FDA approval of Truvada as PrEP
for adolescents
EHR changing from eCW to Epic in
2019
Mutual goal to improve patient
outcomes in HIV prevention
Opportunity for CHPY and SFDPH
leadership in conjunction with new
initiative: Getting to Zero San
Francisco

No standardized protocols
Many changes to clinic workflow
High rate of clinical staff turnover

Threats
•
•
•
•

Potential patient refusal of PrEP
Cultural stigma
Financial cost of PrEP
Low HIV risk perception
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Appendix M. AYA ComPrEP Budget Summary

Cost to Implement the AYA ComPrEP

Number of
hours
anticipated to
be spent on
project
implementation

Staff leader for
implementation

Estimated hourly wage
of project manager
1
(FTE)

Project Manager

$42.52

100

$4,252.00 (WAIVED)

$30

9 interviews

$270.00

$20.00 Cost per Kit

15 kits

$300.00
$90.00

In-Depth Interviews
Gift Cards
PrEP Kits/Binder
Evaluation Tools
Estimated cost

Subtotal cost (FTE)

$660.002
(Excluding the Project Manager
cost which is taken through the
SFDPH salary)

1Project manager wage estimate based on average salary for project manager consultant in San
Francisco reported by Glassdoor. Retrieved from https://www.glassdoor.com/Salaries/projectmanagement-consultant-salary-SRCH_KO0,29.htm
2Fund taken from the scholarship received from Jonas.

PROJECT OVERVIEW PAPER

110

Appendix N. Cost-Benefit Estimate

HIV management costs

HIV PrEP (Benefits)

Estimated HIV management lifetime cost:
$480,000
Annual: $20,000+ per year

Estimated PrEP cost:
$13,000 per patient per year

Estimated total cost of HIV management for 5
years: $100,000

Estimated total cost of PrEP for 5 years: $65,000

1Centers for Disease Control and Prevention. (2015). HIV cost effectiveness. Retrieved from
http://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html
2San Francisco Department of Public Health. (2015). HIV Semi-annual surveillance seport.
Retrieved from https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIVSemiAnnualReport122015.pdf

Appendix O. PrEP Tool – California Department of Public Health
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Appendix Q. PrEP Screening Tool – World Health Organization
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Appendix R. Agenda of PrEP Training

PrEP Education Training Workshop for Nurse Practitioners
April 18, 2020
Time

Agenda

9:00 AM – 9:15 AM

Introduction/Overview/Pre-Survey

9:15 AM – 10:00 AM

Module 1: STI and HIV Review

10:00 AM– 11:00 AM

Module 2: Key Elements for Ethical and Effective HIV Prevention
Counseling Practices

11:00 AM – 11:15 AM

BREAK

11:15 AM – 12:30 PM

Module 3: Adolescents, Reproductive Health & SOGI

12:30 PM – 1:00PM

WORKING LUNCH BREAK
PrEP Support with Lyric (PrEP Navigation)

1:00 PM – 1:45 PM

Module 4: Pre-Exposure Prophylaxis

1:45 PM – 3:00 PM

Case Studies
(25 minutes group work)
(40 minutes Debrief/Post-Survey)

3:00 PM – 3:15 PM

Closing Presentation: Living Positively

PROJECT OVERVIEW PAPER
Appendix S. Module 1: The Basic of STI, HIV & AIDS

122

PROJECT OVERVIEW PAPER

123

PROJECT OVERVIEW PAPER

124

PROJECT OVERVIEW PAPER

125

PROJECT OVERVIEW PAPER

126

PROJECT OVERVIEW PAPER

127

PROJECT OVERVIEW PAPER

128

PROJECT OVERVIEW PAPER

129

PROJECT OVERVIEW PAPER

130

Appendix T. Module 3: Key Elements for Ethical and Effective HIV Prevention Counseling
Practices
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Appendix W. Pre-Training Workshop Survey

Doctor of Nursing Practice – Family Nurse Practitioner
School of Nursing and Health Profession | University of San Francisco
Initiating PrEP in Primary Care: Addressing the AYA High-Risk Populations
Pre-Training Workshop Survey
Section I. Information About You
Direction: Please put a check on the box next to your answer on questions. Some of the other
questions ask for answers in the form of written answers.
1. First and Last Name: ____________________________
2. What is your DNP Track: _________________________
3. Year of Birth: ____________
4. What is your gender? ___ Male

___ Female

5. What is your sexual orientation: _____ Asexual
_____ Heterosexual/Lesbian

___ Transgender ___ Other Identification
_____ Bisexual

_____Homosexual

___ Other; Specify: _______________

___ Pansexual

_____ Homosexual/Gay
_____Queer

___ Prefer not to answer

6. Have you attended a PrEP training before? _____ Yes; Describe: ____________________
_______________________________________________________________

_____ No

7. Do you have experience providing PrEP services to clients? _____ Yes; Describe: _______
_______________________________________________________________

_____ No

8. Do you have any experience working on HIV issues in the past? _____ Yes; Describe: _____
_______________________________________________________________

_____ No

Section II. Knowledge About HIV and PrEP
Direction: True or False. Please put a check on the line next to your answer on questions.
1. HIV is preventable.
_____ True _____False
2. HIV infection is curable. A person infected with HIV can access cure at treatment clinics
or hospitals. _____ True _____False
3. There is a vaccine available to prevent HIV infection. _____ True _____False
4. Children born to HIV-positive women are infected with HIV at birth.
_____ True _____False
5. After a needle prick injury with a needle from an HIV-infected person, the chance of
contracting HIV is less than 1%. _____ True _____False
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6. After a needle prick injury with a needle from an HIV-infected patient, immediately
gently expressing blood from the puncture site reduces the risk of contracting HIV
infection. _____ True _____False
7. After a needle prick injury with a needle from an HIV-infected person, a health worker
may take HIV medications to reduce the chance of contracting HIV infection.
_____ True _____False
8. One can be identified as HIV-positive by the way the person looks (e.g. signs and
symptoms like skin ulcers, weight loss). _____ True _____False
9. If a person has a sexually transmitted infection (STI), his/her chance of getting HIV is
higher. _____ True _____False
10. A person will automatically get infected with HIV once he/she has sexual intercourse
with a person living with HIV. _____ True _____False
11. A person with HIV who is undetectable is considered infectious. He/she is likely to
transmit the virus to his/her partners through sexual intercourse.
_____ True _____False
12. Daily PrEP can prevent HIV transmission through sex for up to more than 90%.
_____ True _____False
13. Daily PrEP can reduce the risk of acquiring HIV among people who inject drugs by 30%.
_____ True _____False
14. For PrEP to be effective against HIV infection should be taken once daily and should be
taken continuously for 7 days before engaging in vaginal sex.
_____ True _____False
15. Using condoms can prevent HIV transmission and other STIs.
_____ True _____False
16. The use of condoms should be promoted to prevent HIV infection.
_____ True _____False
17. The use of condoms should not be promoted if a person is on PrEP.
_____ True _____False
18. A person who is at high risk for HIV and other STIs should be tested once a year for
HIV. _____ True _____False
19. A person who has no sexual partner is not at risk for HIV. He/she should never be tested
for HIV. _____ True _____False
20. Heterosexual men and women are not at risk for HIV infection and are not recommended
for PrEP. _____ True _____False
21. There is no alternative to daily dosing of PrEP. Other PrEP dosing is ineffective to
prevent HIV transmission. _____ True _____False
22. There is only one PrEP regimen available in the market to prevent HIV infection so it is
easy to prescribe. _____ True _____False

Section III. Enabling or Non-Stigmatizing Attitudes
Direction: The following items are intended to measure people's opinions about issues
surrounding HIV and AIDS and PrEP for adolescents. Responses will be used to gauge the
enabling versus stigmatizing attitudes related to HIV and PrEP.
Enabling Attitude Items

Strongly
Agree

Agree

Neither
Disagree
Agree Nor

Strongly
Disagree
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Disagree

In my opinion, persons living with
HIV deserve their illness.
People who are HIV positive should
be encouraged to keep their diagnosis
to themselves.
People who test positive for HIV
should not engage in any sexual
activity.
I am uncomfortable providing
care for an HIV infected person.
A person who is HIV positive should
not be allowed to work as a health
worker.
I have the right to know the HIV
status of the patients/clients in our
practice/unit/department, including
those who are not under my care.
I am willing to work in the same
unit/office with a colleague who is
HIV-positive.
Health care workers should be
required for an HIV antibody test
before engaging in any hospital or
clinical practice.
I have the right to know if someone
in our workplace is HIV-positive.
Homosexual men should be allowed
to donate blood.
Condoms are for married people
only. Adolescents should be
prohibited from using condoms.
A person who is HIV-positive should
be mandated to tell their partners
about their HIV status.
As a professional health worker, I
have the duty to educate the public on
HIV and PrEP.
It is embarrassing to talk about sex
and condom use to clients; therefore,
I should not initiate to talk about it
with my clients or patients.
Adolescents and young adults,
including those below 18 years of
age, who are at high risk of HIV
infection, should be offered PrEP.
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Parents of adolescents, particularly
those below 18 years of age, who are
on PrEP should always be involved in
their care.
Counseling should be a part of any
PrEP program.
Same-Day PrEP should be made
available and offered to adolescents
at-risk for HIV.
Alternative PrEP dosing such as
event-based dosing should be made
available to adolescents.
Non-clinician staff (nurses, medical
assistants, health workers) should
take an active role in adolescents
PrEP follow-up and monitoring.
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Appendix X. Post-Training Workshop Evaluation
Doctor of Nursing Practice – Family Nurse Practitioner
School of Nursing and Health Profession | University of San Francisco
Initiating PrEP in Primary Care: Addressing the AYA High-Risk Populations
Post-Training Workshop Evaluation Survey
Section I. Information About You
Direction: Please put a check on the box next to your answer on questions. Some of the other
questions ask for answers in the form of written answers.
1.
2.
3.
4.
5.

First and Last Name: ____________________________
What is your DNP Track: _________________________
Year of Birth: ____________
What is your gender? ___ Male ___ Female ___ Transgender ___ Other Identification
What is your sexual orientation: _____ Asexual _____ Bisexual _____ Homosexual/Gay
_____ Heterosexual/Lesbian _____Homosexual
___ Pansexual
_____Queer
___ Other; Specify: _______________

___ Prefer not to answer

Section II. Evaluation of Presentations & Simulation Activities
Direction: Select all that apply. Please put a check on the line before your answer on
question/statement. Some of the other questions ask for answers in the form of written answers.
As a result of participating in the session "Module 1: The Basic of STI, HIV and AIDS," I am
able to:
_____ Define and differentiate STI, HIV, and AIDS
______ Understand how HIV is transmitted from one person to another
______ Correct misconceptions about HIV transmission
______ Understand how HIV affects the body
______ Learn how HIV and AIDS can be prevented as well as treated and managed

As a result of participating in the session "Module 2: Key Elements for Ethical and Effective
HIV Prevention Counseling Practices," I am able to:
______ Describe the importance of HIV counseling
______ Identify the DOs and DONTs of HIV prevention counseling
______ Describe key points in PrEP counseling
______ Describe what is provider-initiated counseling and Testing (PICT)
_______ Describe what is client-initiated counseling and Testing (CICT)
As a result of participating in the session "Module 3: AYA and The SOGI Initiative," I am better
able to:
______ Describe the characteristics of adolescents and young adults (AYA), and transgender
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AYA
______ Identify the health risks and solutions for AYA
______ Describe the difference of sex, sexual orientation, and gender identity.
______ Assess, plan, and intervene for an AYA client who may visit to our clinic for primary
care
As a result of participating in the session "Module 4: Pre-Exposure Prophylaxis for AYA," I am
able to:
______ Describe what PrEP is, medication available, and its indication.
______ Describe PrEP effectiveness, side effects, and benefits.
______ Identify the barriers of PrEP use in adolescents and young adults.
______ Understand PrEP resources, guidelines, and algorithm.
______ Develop confidence to prescribe PrEP in our practice

Enabling Attitude Items

Strongly
Agree

Agree

Neither
Disagree
Agree Nor
Disagree

Strongly
Disagree

Presenter: Igor Mocorro, MPH, RN,
PHN. This speaker's presentation
skills were effective for the content
presented.
Overall, I believe my knowledge and
confidence to prescribe PrEP to
adolescents and young adults in my
practice has increased.

List at least 3 changes that you will initiate in your practice related to advancing the health of
adolescents and young adults?
1) ___________________________________________________________________________
2) ___________________________________________________________________________
3) ___________________________________________________________________________
Any comments about the simulation activity today? _______________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
Section III. Knowledge About HIV and PrEP
Direction: True or False. Please put a check on the line next to your answer on questions.
1. HIV is preventable.
_____ True _____False
2. HIV infection is curable. A person infected with HIV can access cure at treatment clinics
or hospitals. _____ True _____False
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3. There is a vaccine available to prevent HIV infection. _____ True _____False
4. Children born to HIV-positive women are infected with HIV at birth.
_____ True _____False
5. After a needle prick injury with a needle from an HIV-infected person, the chance of
contracting HIV is less than 1%. _____ True _____False
6. After a needle prick injury with a needle from an HIV-infected patient, immediately
gently expressing blood from the puncture site reduces the risk of contracting HIV
infection. _____ True _____False
7. After a needle prick injury with a needle from an HIV-infected person, a health worker
may take HIV medications to reduce the chance of contracting HIV infection.
_____ True _____False
8. One can be identified as HIV-positive by the way the person looks (e.g. signs and
symptoms like skin ulcers, weight loss). _____ True _____False
9. If a person has a sexually transmitted infection (STI), his/her chance of getting HIV is
higher. _____ True _____False
10. A person will automatically get infected with HIV once he/she has sexual intercourse
with a person living with HIV. _____ True _____False
11. A person with HIV who is undetectable is considered infectious. He/she is likely to
transmit the virus to his/her partners through sexual intercourse.
_____ True _____False
12. Daily PrEP can prevent HIV transmission through sex for up to more than 90%.
_____ True _____False
13. Daily PrEP can reduce the risk of acquiring HIV among people who inject drugs by 30%.
_____ True _____False
14. For PrEP to be effective against HIV infection should be taken once daily and should be
taken continuously for 7 days before engaging in vaginal sex.
_____ True _____False
15. Using condoms can prevent HIV transmission and other STIs.
_____ True _____False
16. The use of condoms should be promoted to prevent HIV infection.
_____ True _____False
17. The use of condoms should not be promoted if a person is on PrEP.
_____ True _____False
18. A person who is at high risk for HIV and other STIs should be tested once a year for
HIV. _____ True _____False
19. A person who has no sexual partner is not at risk for HIV. He/she should never be tested
for HIV. _____ True _____False
20. Heterosexual men and women are not at risk for HIV infection and are not recommended
for PrEP. _____ True _____False
21. There is no alternative to daily dosing of PrEP. Other PrEP dosing is ineffective to
prevent HIV transmission. _____ True _____False
22. There is only one PrEP regimen available in the market to prevent HIV infection so it is
easy to prescribe. _____ True _____False

Section IV. Enabling or Non-Stigmatizing Attitudes
Direction: The following items are intended to measure people's opinions about issues
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surrounding HIV and AIDS and PrEP for adolescents. Responses will be used to gauge the
enabling versus stigmatizing attitudes related to HIV and PrEP.
Attitude Items

In my opinion, persons living with HIV
deserve their illness.
People who are HIV positive should be
encouraged to keep their diagnosis to
themselves.
People who test positive for HIV
should not engage in any sexual
activity.
I am uncomfortable providing care for
an HIV infected person.
A person who is HIV positive should
not be allowed to work as a health
worker.
I have the right to know the HIV status
of the patients/clients in our
practice/unit/department, including
those who are not under my care.
I am willing to work in the same
unit/office with a colleague who is
HIV-positive.
Health care workers should be
required for an HIV antibody test
before engaging in any hospital or
clinical practice.
I have the right to know if someone in
our workplace is HIV-positive.
Homosexual men should be allowed to
donate blood.
Condoms are for married people only.
Adolescents should be prohibited from
using condoms.
A person who is HIV-positive should
be mandated to tell their partners about
their HIV status.
As a professional health worker, I have
the duty to educate the public on HIV
and PrEP.
It is embarrassing to talk about sex and
condom use to clients; therefore, I
should not initiate to talk about it with

Strongly Agree
Neither
Disagree Strongly
Agree
Agree Nor
Disagree
Disagree
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my clients or patients.
Adolescents and young adults,
including those below 18 years of age,
who are at high risk of HIV infection,
should be offered PrEP.
Parents of adolescents, particularly
those below 18 years of age, who are
on PrEP should always be involved in
their care.
Counseling should be a part of any
PrEP program.
Same-Day PrEP should be made
available and offered to adolescents atrisk for HIV.
Alternative PrEP dosing such as eventbased dosing should be made available
to adolescents.
Non-clinician staff (nurses, medical
assistants, health workers) should take
an active role in adolescents PrEP
follow-up and monitoring.
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Appendix Y. Clinicians Knowledge on HIV and AIDS, and PrEP (n=19)
Knowledge Items
Correct Responses (%)
Pre-Test
Post Test
HIV is preventable. (T)
19 (100)
19 (100)
Daily PrEP can prevent HIV transmission through sex for up to more
19 (100)
19 (100)
than 90%. (T)
The use of condoms should be promoted to prevent HIV infection. (T)
19 (100)
19 (100)
The use of condoms should not be promoted if a person is on PrEP. (F)
19 (100)
19 (100)
If a person has a sexually transmitted infection (STI), his/her chance of
18 (95)
19 (100)
getting HIV is higher. (T)
Heterosexual men and women are not at risk for HIV infection and are
18 (95)
19 (100)
not recommended for PrEP. (F)
A person who has no sexual partner is not at risk for HIV. He/she should
17 (89)
19 (100)
never be tested for HIV. (F)
Using condoms can prevent HIV transmission and other STIs. (T)
16 (84)
19 (100)
Truvada is the only PrEP regimen available in the market to prevent
11 (58)
19 (100)
HIV infection so it is easy to prescribe PrEP. (F)
There is no alternative to daily dosing of PrEP. Other PrEP dosing is
10 (53)
19 (100)
ineffective to prevent HIV transmission. (F)
HIV infection is curable. A person infected with HIV can access cure at
17 (89)
18 (95)
treatment clinics or hospitals. (F)
After a needle prick injury with a needle from an HIV-infected person, a
16 (84)
18 (95)
health worker may take HIV medications to reduce the chance of
contracting HIV infection. (T)
One can be identified as HIV-positive by the way the person looks (e.g.
17 (89)
18 (95)
signs and symptoms like skin ulcers, weight loss). (F)
A person will automatically get infected with HIV once he/she has
18 (95)
18 (95)
sexual intercourse with a person living with HIV. (F)
There is a vaccine available to prevent HIV infection.
18 (95)
17 (89)
After needle prick injury with a needle from an HIV-infected person, the
13 (68)
17 (89)
chance of contracting HIV is less than 1%.
Children born to HIV-positive women are infected with HIV at birth.
15 (79)
16 (84)
A person with HIV who is undetectable is considered infectious. He/she
7 (37)
12 (63)
is likely to transmit the virus to his/her partners through sexual
intercourse.
A person who is at high risk for HIV and other STIs should be tested
0 (0)
11 (58)
once a year for HIV.
After needle prick injury with a needle from an HIV-infected patient,
9 (47)
11 (58)
immediately gently expressing blood from the puncture site reduces the
risk of contracting HIV infection.
Daily PrEP can reduce the risk of acquiring HIV among people who
4 (21)
7 (37)
inject drugs by 30%.
For PrEP to be effective against HIV infection should be taken once
4 (21)
7 (37)
daily and should be taken continuously for 7 days before engaging in
vaginal sex.

